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There is a great demand to develop new therapeutic strategies to treat cancers. 
Of the potential therapeutic strategies, cancer testis antigen SSX2 has shown 
promising effects for the treatment of different cancers. To produce the quantities of 
SSX2 required for the human Phase I/II proof-of-principle clinical trials, improved 
production and secretion of SSX2 were studied in two microbial systems, Escherichia 
coli and Pichia pastoris.  
The first part of this work shows the development of a production process for 
SSX2 antigen from E. coli strain C41(DE3), resulting in a yield of 1.1 g L-1 as 
inclusion bodies. Urea-solubilized SSX2 inclusion bodies were purified by 
immobilized nickel affinity, anion exchange and hydrophobic interaction 
chromatography. Purified SSX2 was characterized by ELISA and recognized by 
human sera containing anti-SSX2 antibodies. 
In the second part of this study, further process development and production 
scale up of SSX2 were carried out in the Cornell/LICR cGMP facility. The yield, 
endotoxin content and purity of SSX2 were improved in the newly developed process. 
The result of a 10 L scale development run is also presented.  
The third part of this work focused on the improvement of SSX2 secretion by 
P. pastoris as a means to produce a delayed-type hypersensitivity (DTH) skin test 
reagent for SSX2 cancer vaccine. SSX2 was minimally secreted by P. pastoris. 
Deletion of the SSX2 C-terminal nuclear localization signal (NLS) did however 
 improve secretion. NLS was responsible for accumulation and misfolding of SSX2 in 
endoplasmic reticulum (ER) and deletion of NLS improved SSX2 folding inside the 
ER to facilitate its secretion. Production of SSX2 without NLS was scaled-up, 
resulting in a yield of 21.6 mg L-1.  
The last part of this work reveals the proteome of different fermentation 
culture media of P. pastoris as a means to enhance recombinant protein purification 
and secretion. The study of the proteome of different P. pastoris cultures indicates that 
most proteins exhibit acidic isoelectric points including naturally secreted and 
intracellular proteins. This study provides host cell protein profiles in different 
fermentation culture media and suggests potential biotechnology applications based on 
the discovery of these proteins.  
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CHAPTER 1 
INTRODUCTION 
Recombinant protein expression in Escherichia coli and Pichia pastoris  
E. coli as a protein expression host  
Recombinant DNA technology has changed the way to produce proteins and 
has increased their availability in research and industry. The very first 
biopharmaceuticals such as recombinant insulin and recombinant human growth 
hormone were produced from Escherichia coli and marketed in the early 1980s. 
Before this time, these proteins were only made available by extraction from natural 
sources. Since then, due to its well-characterized genome, mature tools for genetic 
manipulations and efficient expression of the target gene, E. coli has become an 
attractive expression system to produce heterologous proteins from different origins. 
Several factors, such as strains, expression vectors, promoter strength, 
translation regulation, codon usage and fermentation strategies, have been reported to 
affect the level of recombinant protein expression in E. coli (40). Among strains, E. 
coli K12 and B strains, e.g. BL21, are most widely used to express non-glycosylated 
peptides and proteins. In recent years, pET vectors containing the T7 bacteriophage 
promoter (commercialized by Novagen, Madison, WI) gained increasing popularity 
for production of different recombinant proteins. Typically, this system requires a host 
strain lysogenized with a DE3 phage fragment, encoding the T7 RNA polymerase 
under the control of the IPTG-inducible promoter lacUV5 (59). Because the T7 
promoter is vigorously induced by, and very specific to, its own T7 RNA polymerase, 
high expression level of recombinant protein can be achieved and well-controlled. E. 
coli BL21(DE3) or its derivative C41(DE3) are usually used as the host in 
  2 
combination with the pET vector system. Particularly, the C41(DE3) strain was found 
to be a better host for expressing toxic proteins compared to BL21(DE3) because of 
one uncharacterized mutation, preventing the cell death associated with the expression 
of toxic proteins. Later the mutations in the UV5 promoter governing expression of T7 
RNA polymerase were found to be the key to the improved toxic protein 
overexpression in C41 strain (68).  
The so-called codon bias also poses another challenge for expressing 
heterologous protein in E. coli. The frequencies with which genetic codons are used to 
translate protein vary significantly between different organisms. Preferred codons 
correlate with abundance of cognate tRNAs available within cells. Sometimes, the 
cells will also adjust protein expression level by using different genetic codons (36). 
The effect of codon bias on heterologous protein expression is obvious by decreasing 
the protein translation rate due to the rare codons used by E. coli. Fortunately, this 
problem can be addressed by changing the problematic codons to E. coli preferred 
codons, or by the coexpression of cognate tRNA genes such as coexpression with 
pRARE plasmid in expression strain (17). High cell density fermentation is normally 
used to increase the productivity of recombinant protein in E. coli using a fed-batch 
feeding strategy. Different feeding controls have been developed including DO-state 
and pH-state controls to avoid overfeeding that accumulates acetic acid in the culture 
media, inhibiting both cell growth and recombinant protein production (44). 
Expression of recombinant protein can be either in the cytoplasm or be 
secreted to periplasm and extracellular space. In cytoplasmic expression, protein can 
be soluble or aggregated as inclusion bodies (IB) (Figure 1-1), which depends on 
intrinsic property of protein sequence or other cultivation parameters such as promoter 
strength and cultivation temperature (43). IB formation is mainly due to inappropriate  
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Figure 1-1. Images of E. coli inclusion bodies. Visualization of inclusion bodies in E. 
coli producing elongation factor Tu (EF-Tu) of Streptomyces aureofaciens by 
transmission electron microscope (A; bar = 1µm), phase-contrast optical microscope 
(B; bar = 5µm) and scanning electron microscope (C; bar = 1µm) of purified inclusion 
bodies. (Nguyen et al., 2005) 
 
 
 
 
 
 
Figure 1-2. Recombinant protein secretion pathways in E. coli. Three different 
secretion pathways, type I, type II and TAT, which have been used for recombinant 
protein secretion in E. coli either to extracellular space or periplasm . (Wickner and 
Schekman, 2005) 
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folding and overexpression of recombinant protein. Most IB-forming proteins require 
solubilization in chaotropic agents such as urea and guanidinium chloride, then refold. 
However, some vaccines like NY-ESO-1 are formulated in 4M urea which do not 
require protein refolding upon immunizing cancer patients (4, 51). Gram-negative 
bacteria have generally used five different secretion pathways for secreted proteins 
such as degradative enzymes, toxins and pathogenic factors. Among them, type I 
mechanisms have been reported to secrete different recombinant proteins in E. coli to 
extracellular space. Type II secretion have been successfully explored to transport 
recombinant proteins to periplasm. However, it is rarely used for extracellular 
secretion as it has a vey narrow substrate specificity for translocation across the outer 
membrane (49). More recently, a novel twin-arginine translocation (TAT) system was 
discovered and used for secretion of several recombinant proteins including antibody 
fragment (Figure 1-2) (24). One of the advantages for secreting recombinant protein in 
E. coli is that protein is generally correctly folded into its native state where protein 
refolding is not necessary. However, the yield is usually low compared to IB and 
improved secretion requires overexpression of some periplasmic factors or chaperones 
and use of the leaky strains (49).   
Even though E. coli has been considered as an excellent recombinant protein 
expression host, there are some disadvantages in this system such as inability to 
perform posttranslational modifications, inefficient secretion machinery and presence 
of endotoxin in the final purified recombinant protein. Endotoxin is the 
lipopolysaccharide (LPS) of gram-negative bacteria and its high concentration in the 
recombinant therapeutics can cause a variety of inflammatory responses in humans 
(28). Therefore, endotoxin level is considered an important quality criterion for E. 
coli-derived recombinant therapeutics. The limit of endotoxins is set at 5 endotoxin 
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units (EU) per kg patient weight and hour for both intravenous and intramuscular 
applications according to United States Pharmacopeia. One EU is roughly equivalent 
to 100 pg of endotoxin, Therefore, the amount of the endotoxin that can be 
administrated to a patient is depended on the therapeutic dose and the endotoxin 
concentration of the therapeutics. The disadvantages for using E. coli as a expression 
host have been constantly challenged and addressed by scientists. For example, the 
first discovered N-linked glycosylation pathway in bacteria Campylobacter jejuni has 
been engineered into E. coli to produce recombinant glycoprotein (67). Recent 
advances in understanding protein secretion in bacteria also show great promise 
leading to new strategies to facilitate the secretion of recombinant protein (31). 
Several technologies such as anion exchange chromatography, positive charged depth 
filters, and detoxification of endotoxin by modification of its structure by 
overexpression of H. pylori genes have been developed and studied to remove or 
detoxify endotoxin from recombinant protein solutions (14, 47). 
P. pastoris as a protein expression host  
The methylotrophic yeast Pichia pastoris was also widely used for high yield 
expression of various recombinant proteins by secretion into the culture medium or 
intracellular localization. P pastoris has evolved a specific pathway with unique 
enzymes such as alcohol oxidase, catalase and dihydroxyacetone synthase to utilize 
methanol as the sole carbon and energy source. The reactions occur in peroxisomes 
followed by metabolic steps in cytoplasm to dissimilate methanol (Figure 1-3) (13). 
There are two genes that encode alcohol oxidase: AOX1 and AOX2. AOX1 accounts 
for the majority of alcohol oxidase activity in cells, as it has a very strong and tightly 
regulated promoter. Transcription of AOX1 is repressed with the presence of other 
carbon sources such as glucose and glycerol. When cells are grown in the medium  
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Figure 1-3. Methanol utilization pathway in methylotrophic yeasts including P. 
pastoris. The key enzymes involved in methanol metabolism are: AOX: alcohol 
oxidase, CAT: catalase, DAS: dihydroxyacetone synthase, and FDH: formate 
dehydrogenase. (Hartner and Glieder, 2006) 
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where methanol is the only carbon source, expression of AOX1 is induced where 
alcohol oxidase can comprise over 30% of the total intracellular proteins and 
peroxisomes can account for up to 80% of cytoplasmic space (32).  
Over 400 recombinant proteins have been produced in P. pastoris. Since P. 
pastoris is also a eukaryote, it provides the potential to produce soluble and correctly 
folded recombinant proteins and offers significant advantages over the E. coli 
expression system for the production of many heterologous eukaryotic proteins (11). 
A number of different P. pastoris strains with various genotypes are available. X-33 is 
the wild type strain where both AOX1 and AOX2 are functional to utilize methanol and 
is designated as Mut+ strain, i.e. methanol utilization plus strain. The KM71H strain, 
however, contains a non-functional AOX1 and relies on the AOX2 gene to produce 
alcohol oxidase, leading to a slow growth on methanol-containing media. Its 
phenotype is termed methanol utilization slow (Muts). The SMD1168H strain is 
defective in the vacuole peptidase A (pep4) which is responsible for activation of 
carboxypeptidase Y and protease B1. This strain is used to reduce the proteolytic 
activity for some recombinant proteins. Strains such as GS115, SMD1168 and KM71 
are defective in the histidine dehydrogenase gene (his4) and can be selected on their 
ability to grow in non-histidine containing media (21). Depending on the goals and 
types of recombinant proteins, these strains provide useful tools to improve 
recombinant protein expression.  
The AOX1 promoter has been the most widely reported and used of all the 
available promoters in P. pastoris (12). Because alcohol oxidase has a poor affinity for 
oxygen, P. pastoris can compensate its ability by an immensely upregulated AOX1 
promoter when methanol is the only carbon source. This promoter can drive high 
levels of recombinant protein production with a single integrated copy of the 
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expression cassette. Another advantage of this promoter is that it can be switched on 
and off by manipulating the presence of different carbon sources in the culture media. 
The constitutive promoter, GAP (glyceraldehyde 3-phosphate) promoter, is also 
available in P. pastoris without the need of methanol induction to produce 
recombinant proteins. Different carbon sources, such as glucose, glycerol, oleic acid 
and methanol, can be used to culture the cells to express proteins. Several studies have 
shown some proteins achieved high levels expression by using the GAP promoter (70). 
However, one general advantage of using the GAP promoter instead of the AOX1 
promoter is that methanol, which is considered a fire hazard and contaminant for the 
production of recombinant proteins, is not required.  
Both intracellular expression and extracellular secretion of recombinant protein 
are applicable in P. pastoris. This usually depends on the protein to be expressed. If 
the target protein does not secrete in its native form, forcing its secretion through the 
folding pathway may result in misfolding or alter its properties due to incorrect post-
translational modifications. Indeed, many proteins have been expressed successfully in 
the intracellular milieu in P. pastoris, particularly for some membrane-associated 
proteins such as the hepatitis B surface antigen (66). However, it is difficult to purify 
the target protein as it typically represents less than 1% of the total intracellular 
proteins (21). On the other hand, the secretion of recombinant protein into the culture 
media offers several advantages such as avoiding toxicity of intracellular accumulated 
recombinant protein and simplification of the protein purification. In addition, entering 
of the protein through secretory pathway allows post-translational events such as 
glycosylation, proteolytic maturation and disulfide bond formation. These properties 
are necessary for some recombinant mammalian proteins to ensure their biological 
activity (46). In fact, the secretion of properly folded recombinant proteins is one of  
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Figure 1-4. Examples of homologous recombination of expression cassettes into P. 
pastoris genome. (A) Gene insertion occurs at the his4 locus of Pichia genome by 
single cross over event between HIS4 gene on the expression plasmid, resulting in a 
His4+ transformant. (B) Gene replacement is achieved by double cross over event 
between the upstream and downstream AOX1 gene of the genome and the expression 
vector. This results in the complete elimination of AOX1 gene coding region, resulting 
in a His4+ and Muts transformant. (Pichia Manual, Invitrogen) 
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the crucial factors taken into account when yeast is considered as a preferred 
expression host. Different secretion signals, including alpha-mating pre-pro leader 
sequence (α-MF), acid phosphatase signal (PHO) and invertase signal (SUC2), have 
been used to secrete recombinant protein in P. pastoris. However, there is no general 
rule of which leader signal is the best signal for recombinant protein secretion. Instead, 
trial and error experiments are often required to identify the optimal secretion signal 
for a specific recombinant protein.  
Once the expression vector is constructed, it is integrated into P. pastoris 
genome at the specific locus by homologous recombination to generate genetically 
stable transformants (Figure 1-4). Integration can occur via gene insertion or gene 
replacement in either a marker gene (e.g. HIS4, ARG4 and URA3) or the AOX1 
promoter. Integration by gene insertion occurs from a single crossover event at a high 
frequency (50-80% of His+ transformants) and tandem multiple recombination events 
can be achieved at the rate of 1-10% of transformants to generate a multicopy strain 
(19). To obtain a gene replacement transformant, an expression vector requires 
digestion and linearization to have double crossover events. This occurs at a frequency 
of 5-25% of total transformants. The remainder of the transformants are the result of 
gene insertion (53). Since the expression cassette is integrated into the Pichia genome, 
there is no need to add antibiotic to maintain the transformed population cells. 
Transformed cells can be selected by either auxotrophic complementation, or 
resistance to antibiotics (e.g. Kanamycin and Zeocin). The latter is used to collect 
multicopy transformants, where the levels of drug resistance correlate to the 
expression cassette copy number.  
To improve recombinant protein production in P. pastoris, fermentation is 
essential as cell density usually correlates with high protein yield. Pichia 
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fermentations are characterized by high cell densities, short fermentation times and the 
use of chemically defined media. It can be categorized into two types of fermentation, 
one-phase and two-phase, which depends on the types of promoter used. When the 
constitutive GAP promoter is used, one carbon source (glucose or glycerol) is used by 
the cells during the fermentation. While using the AOX1 promoter, cells are grown in 
glycerol until it is depleted, then switch to the second phase where gene expression 
begins by feeding methanol into the fermentor. There are several factors affecting 
protein production yield including composition of culture medium, strain, pH, 
dissolved oxygen level, temperature and feeding strategy where the best fermentation 
conditions usually require optimization of these parameters (45). For example, several 
studies have demonstrated that some recombinant proteins, such as insulin-like growth 
factor and A33 single chain antibody (A33scFv), are more stable and produced in high 
yield at pH 3.0, rather than at a higher pH (22).  
To maintain methanol concentration within optimal limits, three different 
methanol-feeding strategies are generally used to achieve high cell density without 
hampering cell growth. First, the methanol-feeding rate is controlled according to the 
methanol concentration in the culture media (22). Second, the methanol-feeding rate is 
adjusted by the dissolved oxygen level by increasing feeding rate when dissolved 
oxygen concentration increases, and vice versa (50). The final strategy is to control the 
feeding rate according to the specific growth rate during the induction phase (20). 
Successes of different strategies have been reported from different fermentation 
cultures expressing different recombinant proteins (45). 
Although the P. pastoris expression system has the benefits of eukaryotic 
folding pathways, its glycosylation machinery is different than humans and other 
mammalian systems. This characteristic impedes recombinant glycoprotein production 
  12 
in P. pastoris because correct glycosylation pattern is important to maintain biological 
activity, stability and low immunogenicity of some proteins (21). Like other 
mammalian cells, yeast N-glycosylation is initiated in the endoplasmic reticulum (ER) 
and then the substrate is transported into the Golgi apparatus for additional trimming 
of the glycan. It is at the Golgi apparatus that yeast display different glycosylation 
pathways, resulting in the production of mostly high-mannose containing 
oligosaccharides. Due to the lack of α-1,3-mannosyltransferase in the Golgi complex, 
P. pastoris has much shorter mannose-containing glycans than those expressed in S. 
cerevisiae (71). However, mannose-containing glycan is a non-human glycosylation 
and hence immunogenic, which might cause adverse immune responses. Recently, 
scientists have showed that it is possible to engineer the glycosylation pathway in P. 
pastoris to produce humanized glycoprotein by replacing endogenous glycosylation 
enzymes with five eukaryotic enzymes to produce complex human N-glycan protein 
(8). This technology further expands the application of using P. pastoris for 
recombinant protein expression.  
 
Cancer testis antigens 
Identification of cancer testis (CT) antigens  
In the early 1990s, Boon and his colleagues reported isolation of a human 
tumor, termed melanoma antigen-1 or MAGE-1, from a melanoma cancer patient who 
elicited cytotoxic T lymphocyte (CTL) responses that recognized autologous tumor 
cells (64). The expression of MAGE-1 was later found not only in melanoma but also 
in other cancer types. In normal tissues, its expression was ordinarily restricted to the 
testes (25). The technique used in studying this antigen was called T-cell epitope 
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cloning and led to the identification of similar tumor antigens such as B melanoma 
antigen (BAGE) and G antigen (GAGE) (65). Although identification of these new 
antigens provides potential targets for immunogenic cancer vaccines, this approach 
was technically challenging.  
An approach developed by Sahin and colleagues called SEREX (serological analysis 
of recombinant tumor cDNA expression libraries with autologous serum) circumvents 
the limitations of T-cell epitope cloning in identifying more tumor antigens (Figure 1-
5). It was designed to isolate tumor antigens that elicit high titer immunoglobulin G 
(IgG) responses in cancer patients (55). The first gene identified by SEREX was 
HOM-MEL-40 or synovial sarcoma X breakpoint 2 (SSX2) from a melanoma patient 
(54). Analysis of SEREX protocol on esophageal cancer led to the discovery of NY-
ESO-1 antigen, the most immunogenic tumor antigen known to date identified by 
SEREX (15). Like MAGE-1 and BAGE, SSX2 and NY-ESO-1 were also restricted in 
their expression to testes and different cancers. These characteristics were shared by 
unrelated genes among other tumor antigens. Therefore, Chen and his colleagues 
proposed the term cancer testis (CT) antigens to this type of tumor antigen (55). The 
immunity generated from the CT antigens in cancer patients can be cellular or humoral 
responses. Some antigens elicit both cellular and humoral responses.  
Based on the definition of CT antigens, several techniques including 
representational difference analysis (RDA), differential display, cDNA 
oligonucleotide array analysis and bioinformatic analysis, have been applied to 
identify CT antigens (55). To date, according to the published literature, there are over 
130 genes identified as CT antigens that belong to 83 gene families with some of their 
functions unknown (38). By comparing CT antigen expression data from different 
studies, most of them shared these characteristics including: 1) expression restricted to  
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Figure 1-5. Illustration of SEREX protocol for cloning and identifying human cancer 
antigens eliciting high immunoglobulin G (IgG) antibodies. (Chen, 2004) 
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gametogenic tissues and cancer; 2) coding genes frequently map to chromosome X; 3) 
exist as multigene families; 4) immunogenic in caner patients; 5) heterogeneous 
protein expression in cancer; 6) expression may be associated with tumor progression 
and with tumors of high metastatic potential; and, 7) in vitro activity by 
hypermethylation and/or histone deacetylase inhibitors (55). Importantly, CT antigens 
are immunogenic in cancer patients with restricted expression, and as the result, have 
the potential to be used as a cancer vaccine. 
The mechanism of cancer immunotherapy by CT antigens 
CT antigens represent the ideal targets for cancer immunotherapy, a process that the 
immune system can be trained to attack tumors in the same way that it targets the 
infectious agents. This relies on administration of CT antigens to cancer patients to 
improve their immunity against cancer cells to kill cancer cells. In general, antigen or 
peptides will be delivered to antigen presenting cells such as Dendritic Cells (DC) that 
will degrade the antigen and display as epitopes on the cell surface through a pathway 
called Major Histocompatibility Complex (MHC) class I pathway. DC will later 
present the epitopes to T cells to activate and proliferate tumor-specific cytotoxic T 
lymphocytes (CTL) which can target and kill the cancer cells (Figure 1-6) (29). Since 
testis germline cells are MHC class I negative, the expression and activation of CT 
antigen-specific T lymphocytes is highly tumor specific, making CT antignes ideal 
targets for cancer immunotherapy. 
In the initial clinical trial with MAGE-A3 peptides in HLA-A1 patients, 7 out 
of 25 patients showed significant tumor regression (48). The results of the Phase II 
proof-of-concept clinical trial of MAGE-A3 in MAGE-A3 positive patients with stage 
IB or II Non-Small Cell Lung Cancer was promising, and moved on to the Phase III 
trial in 2008 (10). Induction of CD4+ and CD8+ T cells specific to a broad range of NY 
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Figure 1-6. A simplified cartoon illustration of cancer immunotherapy by CT antigens 
(cancer vaccines). The vaccines will be delivered to antigen-presenting cells such as 
dendritic cells to activate the antigen-specific T lymphocytes to kill cancer cells.  
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-ESO-1 epitopes were found in the data from its several ongoing clinical trials against 
different cancers (27). These examples show great promise for the use of CT antigens 
as cancer vaccines, and their successes seem to rely on the identification of 
appropriate antigens and the effective immunization protocol. 
 
SSX2 as a cancer testis antigen 
SSX2 is a CT antigen that is expressed in a wide variety of tumors including 
human melanoma, colon cancer, hepatocarcinoma, breast carcinoma (60, 61). Its gene 
is located on X chromosome with at least four other similar genes (SSX1, SSX3, SSX4 
and SSX5) (35). SSX2 has been shown to elicit both spontaneous humoral and cellular 
immune responses in cancer patients. By analyzing a tumor-infiltrated lymph node of 
a melanoma patient bearing an SSX2-expressing tumor, Ayyoub and colleagues have 
recently identified the first SSX2-derived CD8+ T cell epitope, that corresponds to the 
peptide SSX241–49, and is recognized by specific CTL in an HLA-A2-restricted 
fashion. This study also suggested that SSX241–49-specific CTLs exhibit high tumor 
reactivity, and are selectively expanded during immune responses to SSX-2-
expressing tumors in vivo (3). Other SSX2-derived T cell epitopes recognized by 
CD4+ T cells have also been reported (2). SSX2-specific CD8+ T cells isolated from 
hepatocellular carcinoma patients can specifically and efficiently kill tumor cells in 
vitro (9). These studies have demonstrated that SSX2, like MEAG-A3 and NY-ESO-1, 
is a promising cancer vaccine for cancer immunotherapy. 
Other than being a CT antigen, SSX2 is also involved in a chromosomal 
translocation t(X;18)(p11.2;q11.2) characteristically found in 70% of human synovial 
sarcoma (18). The translocation results in a synovial sarcoma translocation gene (SYT)  
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Figure 1-7. Illustration of SSX2 CT antigen. The N-terminal white box covers the 
MHC class one and two epitopes of SSX2 antigen. The C-terminal black box 
represents the bipartite nuclear localization signal which is characterized by two basic 
amino acid domains (underlined) required for nucleus targeting.   
 
 
 
 
 
 
 
 
 
Figure 1-8. The basic and general recombinant protein purification process.  
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fused most C-terminal SSX2 to the C-terminus of SYT to form SYT-SSX2 fusion 
believed to be a possible transcription activator for aberrant transformation of synovial 
sarcoma (52). SSX2 is a nuclear protein containing a C-terminal bipartite nuclear 
localization signal (NLS) that is responsible for the translocation of SYT-SSX2 and 
SSX2 to the nucleus (26). Inspections of the SSX2 sequence revealed a high content in 
charged amino acid and an acidic C-terminal tail that is highly conserved among the 
SSX protein family and a predicted hydrophilic protein (Figure 1-7) (23).  
 
Recombinant protein purification and process development  
Protein purification  
Expressed recombinant proteins from microbial or mammalian cells are 
required purification by downstream processing (DSP). This process is critical and 
challenging, especially for a therapeutic protein which usually requires over 99% 
purity with biological activity. DSP contains several purification steps including cell 
separation or lysis, preparative buffer exchange and several chromatographic steps. 
Among these processes, chromatography is the most efficient technique to separate the 
recombinant protein from the host proteins, however, its development has traditionally 
relied on trial and error approaches. Accordingly, large numbers of laborious runs and 
fraction analyses, from several hours to days, may be required to develop a successful 
purification methods for a specific protein. 
The rule of thumb of recombinant protein purification includes four steps: 
clarification and concentration, primary contaminants removal, intermediate 
purification and polishing (Figure 1-8). For the first step, a centrifuge is usually used 
to collect the cells or supernatant, depending on localization of expressed protein. Cell 
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lysis is required if the protein is expressed in an intracellular manner. The use of 
membrane technology to remove contaminants or perform buffer exchange by cross 
flow filtration usually follows (63). The goal of primary contaminant removal is to 
provide a significant increase in the purity of the recombinant protein with respect to 
the starting material. There are several techniques applied in this step, including 
protein precipitation and affinity chromatography. For IB, high g force centrifugation 
and cross flow filtration are often used for primary contaminants removal. 
Intermediate purification is usually achieved by the combination of chromatography, 
cross flow filtration and other filtration steps (58). The chromatographic methods used 
in this step are ion exchange (IEX) and hydrophobic interaction (HIC) 
chromatography with the characteristics of high protein binding capacity and flow 
rate. Polishing steps are used to provide a final product with correct quality and purity 
prior to formulation. The targets for separation are usually isoforms, aggregates and 
other chemicals of the final products. Therefore, high resolution but low capacity size 
exclusion chromatography (SEC) is usually used for this step. Affinity and other 
chromatography might also be used to improve the purity or remove contaminants at 
the last polishing step (14).  
Process Development 
In the process of protein therapeutic discovery to administration in the clinic, 
development scientists are usually responsible for protein expression, fermentation 
and purification to provide clinical grade material for Phase I/II safety and proof-of-
concept trials (5, 33, 39). Development scientists usually work on both the lab and 
manufacturing scale to optimize recombinant protein production processes to meet 
ambitious timelines and maintaining standards. Design of a productive and economical 
process requires not only a thorough understanding of the nature of the target protein, 
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but also establishing platform technologies. The latter includes rapid generation of an 
expressing system, various fermentation protocols and different generic purification 
processes for different proteins such as antibodies, inclusion bodies and secreted 
therapeutics (33). The key to the success of a process development effort is usually 
achieved when an interdisciplinary team of scientists, engineers and analytical experts 
working closely together.  
 
Proteomic study and its applications in recombinant protein production 
Proteomics: its technology and development 
Proteomics is the study of protein properties (expression level, post-
translational modification, interactions etc.) on a large scale to obtain a global and 
integrated view of disease processes, cellular processes and networks at the protein 
level (7). Proteomics is technically complicated because it includes the 
characterization and functional analysis of all proteins that are expressed by a genome. 
It is also very dynamic because protein expression levels depend on complex 
regulatory systems. The core technologies of proteomics include protein separation, 
sample preparation and identification. Two-dimensional polyacrylamide-gel 
electrophoresis (2D PAGE) has remained the most efficient and economic way of 
separating complex protein mixtures (7). Protein sample preparation can represent a 
challenge for current proteomics techniques, especially for proteins occurring at a low 
concentration. These proteins are difficult to recover in the processes of precipitation, 
digestion, gel extraction (16). Addition of a liquid chromatography (LC) step can 
complement this limitation to increase sample detection sensitivity. Mass spectrometry 
is used for protein identification, and the success in the identification may vary with 
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the sensitivity of the mass spectrometer, the completeness of the database, the 
presence of isobaric masses, post-translational modifications and other factors (30).  
Two peptide ionization methods, matrix assisted laser desorption ionization 
(MALDI) and electrospray ionization (ESI), demonstrating the high sensitivity and 
ability of less chemical decomposition, have mainly been used for protein 
identification in proteomics (7). MALDI time of flight mass spectrometry (MALDI-
TOF-MS) is an efficient and robust approach for high throughput protein 
identification. With the automation and the software available, over 1000 protein spots 
can be measured by one person per day (42). However, there are two major limitations 
for MALDO-TOF MS. First, it is not sensitive enough to identify low molecular 
weight proteins, which generate fewer peptides for identification. Second, it can not 
identify multiple proteins of a mixture. Protein samples or a separated 2D gel spot 
usually contain more than one protein, hence some proteins will be missed (30). A 
more comprehensive approach to identify proteins is to perform tandem mass 
spectrometry (MS/MS) which normally results in protein identification even with one 
peptide precursor ion. MS/MS also can confirm MS-based protein identifications. 
Another critical advantage for tandem mass spectra is that they allow the sequencing 
of amino acids for the unidentified peptides or peptides belonging to hypothetical 
proteins. In such cases, the amino acid sequences are subjected to a BLAST search for 
protein identification purposes (30).  
Several protein identification techniques such as, LC-MALDI-TOF MS, LC-
MALDI-TOF/TOF, LC-ESI-MS/MS (Figure 1-9), can be used based on different 
purposes. Once the peptide masses of the generated mass spectra have been 
determined, proteins related to these peptides can be identified by software such as 
MASCOT and SEQUEST by comparing masses of peptides generated from a specific  
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Figure 1-9. Summary of common steps in proteomic analysis for protein 
identifications from 2D gel spots or protein solution.  
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database. In some cases, many peptides fail be identified mainly due to an incomplete 
database. The MS BLAST homology search can be used to overcome specific 
limitations imposed by mass spectrometric data and database availability (56).   
Proteomics and process development  
Proteomics techniques and studies have been applied in process development 
to improve recombinant protein production (34). Smales and colleagues have 
conducted a proteomic study of different IgG-producing GS-NS0 cell lines. In this 
study, a significant increase of host proteins, including immunoglobulin binding 
protein (BiP), endoplasmin and protein disulphide isomerase, was correlated with 
monoclonal antibody (MAb) productivities (57). Proteomic profiling of different 
batches of fetal bovine serum (FBS) have found additional growth-related proteins in 
FBS can improve cell viability (72). This information will aid in engineering high-titer 
strains and optimizing culture media to improve recombinant protein production.  
Proteomic analysis of host cell proteins (HCPs) also plays a vital role in cell 
line selection and downstream processing (69). By comparing HCP patterns of 
different cell lines, scientists will be able to select a better protein expression strain in 
perspective of recombinant protein purification. Similar ideas can also be applied to 
select better cultivation conditions (41, 62). Identification of HCPs can reveal the 
identities of crucial contaminants with regard to the recombinant protein, providing 
strategies to remove these contaminants from the final product. Analysis of the 
proteome of secreted proteins (secretome) will also help to identify new secretion 
signals from secreted proteins. Although several studies have demonstrated that 
secreted proteins and their secretion signals can be predicted by analysis of the 
genome sequence, it usually lacks proteomic validation (1). However, the analysis of 
the proteome from the extracellular space normally contains some intracellular 
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proteins. For example, proteomic analysis of the extracellular proteome fraction of 
Corynebacterium efficiens YS-314 had identified 58 proteins. Among these proteins, 
34 were secreted proteins with secretion signals predicted by SignalP, a software 
predicting the presence and location of signal peptide cleavage sites in amino 
acid sequences in different organisms (6). The rest of the proteins could be 
secreted protein by an unconventional secretion pathway or intracellular proteins (37).  
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CHAPTER 2 
EXPRSSION AND PURIFICATION OF THE CANCER ANTIGEN SSX2: A 
POTENTIAL CANCER VACCINE 
Abstract 
SSX2 is a cancer testis antigen expressed in a wide variety of cancers, including 
synovial sarcoma and melanoma.  It holds promise as a potential antigen for cancer 
immunotherapy.  A process for the production of recombinant SSX2 was developed 
by overexpressing a His-tagged fusion protein of SSX2 in Escherichia coli C41 
(DE3).  A T-7 promoter system was employed and a plasmid was introduced into the 
strain to compensate for rare codons in the SSX2 sequence.  The production of SSX2 
was scaled up to a 2 L fermentation that was operated under fed-batch conditions to 
improve productivity.  After 32 hr cultivation, the wet cell mass reached 260 mg/mL, 
with SSX2 produced mainly as inclusion bodies at a concentration of 1.1 g/L.  Urea-
solubilized SSX2 was purified by nickel affinity, ion exchange and hydrophobic 
interaction chromatography.  The recovery of SSX2 was 20%, and over 87% purity 
was obtained with an endotoxin level of 0.11 EU/µg.  The purified recombinant SSX2 
was characterized by ELISA and was shown to be recognized by human sera that have 
been reported to carry anti-SSX2 antibodies. 
 
 
*Originally published as: Huang, C-J., Chen, R., Vannelli, T., Lee, F., Ritter, E., 
Ritter, G., Old, L. J., Batt, C. A. “Expression and purification of the cancer antigen 
SSX2: A potential cancer vaccine.” 2007. Protein Expression and Purification 56:212-
219. Reprint with permission from Elsevier.   
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Introduction 
 SSX2 was first identified by serological analysis of recombinant expressed 
clones (SEREX) from a cDNA library derived from a human melanoma (18).  The 
SSX2 gene is located on chromosome 18 (Xp 11.22) fused to the 5’ sequence of SYT, 
a gene encoding a putative transcriptional activation protein.  Further studies found 
that the SSX2 gene was not only expressed in human melanoma but also in other 
malignancies, including colon cancers, hepatocarcinomas and breast carcinoma (18, 
26).  Expression studies in normal tissue showed that SSX2 transcripts were found 
mainly in testis tissue with low levels in the thyroid (8).  In addition, different types of 
cancers elicit both humoral and cellular immune responses against the expressed SSX2 
antigen (2, 4, 16, 18, 20).  Since it is not expressed in normal tissue except in testis, 
but is in different malignancies and antibodies are found against it in some cancer 
patients, SSX2 is characterized as a cancer testis (CT) antigen (19).  
CT antigens are tumor antigens exclusively expressed in tumor cells that also 
elicit immunogenicity in cancer patients.  CT antigens are not expressed in normal 
tissues with the exception of testis germ cells and occasionally in female reproductive 
organs (19).  Fortunately, testis germ cells are known to be MHC class I negative 
which are not recognized by T cells. Thus, CT antigens are highly tumor-specific and 
considered as an ideal cancer vaccine target for cancer immunotherapy (29).  To date, 
several CT antigens, including NYESO-1, MAGE-3 and SSX2, have been identified 
and proven to elicit spontaneous humoral and cell mediated immune responses (19).  
Clinical trials of NYESO-1 and MAGE-3 as cancer vaccines have shown promising 
results (9, 14).  Several studies have shown that the SSX2 antigen can activate CD8+ T 
lymphocyte cells to efficiently kill melanoma and carcinoma cells (1, 4).  To 
determine the safety and efficacy of SSX2 as a therapeutic cancer vaccine, sufficient 
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quantities of it are needed for clinical trials.  
In this study, we developed a process suitable for the large-scale production of 
SSX2 antigen.  Coexpressing a pRARE plasmid with the SSX2 production plasmid 
was first investigated.  The production of SSX2 was then scaled up to a 2 L bench-top 
fermentor operated with a fed-batch protocol to increase cell biomass and SSX2 yield.  
A purification process that included chromatographic steps including immobilized 
metal (nickel) affinity, anion exchange and hydrophobic interaction was then 
developed to improve the purity and quality of SSX2.  The purified SSX2 was 
characterized by its ability to be recognized by anti-SSX2 antibodies from the sera of 
cancer patients.  
 
Materials and Methods 
Bacterial strain and plasmid construction 
E. coli C41 (DE3) purchased from Lucigen Corporation (Middleton, WI) was 
used as the host stain to express recombinant SSX2 (GenBank accession no. NM 
175698).  A SSX2 N-terminal six His-tag gene was constructed using PCR by placing 
Nde1-6His and Not1 fragments at the N and C termini of the SSX2 gene, respectively.  
The Nde1-NHSSX2-Not1 construct was amplified using the oligonucleotides, 5’-
CATATGCACCACCACCACCACCACAACGGAGACGACGCC-3’and 5’-
GCGGCCGCTTACTCGTCATCTTCCTCAGGGTCGCTG-3’, and plasmid 
pET9a24aSSX2 as a template.  The amplified fragment was then cloned into a pCR2.1 
plasmid using a TOPO TA cloning kit (Invitrogen, Carlsbad, CA) to create plasmid 
pCR2.1-Nde1-NHSSX2-Not1. The expression plasmid, pET9a24aNHSSX2 (Figure 2-
1a) with kanamycin as a selection marker, was constructed by replacing the Nde1-
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Not1 fragment of vector pET9a24a with the Nde1-NHSSX2-Not1 fragment derived 
from pCR2.1-Nde1-NHSSX2-Not1.  The pRARE plasmid (Novagen, Darmstadt, 
Germany), which encodes tRNAs rarely produced in E. coli and uses chloramphenicol 
as a selection maker, was coexpressed in addition to pET9a24aNHSSX2 to improve 
SSX2 antigen production.  
Cultivation of strain  
Shake flasks 
A single colony of E. coli C41 (DE3) bearing pET9a24aNHSSX2 and pRARE 
plasmids was inoculated in 5 ml LB medium (1.0% tryptone, 0.5% yeast extract and 
0.5% sodium chloride) containing 100 µg/ml kanamycin and 36 µg/ml 
chloramphenicol.  For E. coli C41 (DE3) carrying pET9a24aNHSSX2 only, the LB 
medium did not include chloramphenicol.  The cultures were grown overnight at 37℃, 
and used to inoculate a fresh 30 ml of antibiotic-containing LB medium to an initial 
optical density (OD600) of 0.1.  After the culture reached an OD600 of 0.5, isopropyl-β-
D-thiogalactopyranoside (IPTG) was added to a final concentration of 2 mM to induce 
the production of SSX2.  Four hours after induction, the cells were collected, and 
OD600 was normalized to 5.0 to analyze SSX2 production.  
Fermentation  
An overnight culture of E. coli C41 (DE3) bearing pET9a24aNHSSX2 and 
pRARE was grown in 40 ml of production culture medium (0.1 g/L FeSO4·7 H2O, 3 
g/L (NaPO3)6, 2.1 g/L NH4Cl, 1.9 g/L citric acid·monohydrate, 2 ml/L 30 % NH4OH, 
15 g/L yeast extract, 20 g/L glucose, 3.2 mM MgSO47·H2O, 0.2 mg/L MnCl2·4H2O, 
100 µg/ml kanamycin and 36 µg/ml chloramphenicol) at 37℃ until the OD600 reached  
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Figure 2-1. Plasmid construction and SSX2 expression. (a) Restriction map of 
recombinant SSX2 antigen expression plasmid pET9a24aNHSSX2. The 6 His tag 
gene was cloned at the N-terminus of SSX2 gene. The expression of SSX2 antigen 
gene was driven by a T-7 promoter and induced by adding IPTG. (b) SDS-PAGE and 
(c) western blot of SSX2 antigen expression with and without pRARE plasmid in E. 
coli C41 (DE3). Optical density was normalized before analysis. M, molecule weight 
marker; S, SSX2 standard; P, whole cell lysate before induction; SE, soluble protein 
fraction after induction; IS, insoluble protein fraction after induction; W, whole cell 
lysate after induction 
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2.0.  This culture was used to inoculate the fermentor.  The fermentation was carried 
out in a 2 L fermentor (Bioflo 3000, New Brunswick Scientific, Edison, NJ) with an 
initial volume of 800 ml production culture medium.  AFS-Biocommand 
Bioprocessing software version 2.6 (New Brunswick Scientific) was used for data 
acquisition and parameter control.  During the fermentation, the culture was cultivated 
at 37℃ with agitation at 1000 rpm and an air flow rate of 2.5 L/min.  The dissolved 
oxygen (DO) level was maintained at 40% of air saturation, and the air supply was 
supplemented with pure oxygen when needed.  The pH of the culture medium was 
maintained at 6.8 with 5 M NaOH. After glucose was depleted from the initial 
medium, base addition was turned off and the addition of a highly-concentrated 
glucose feed (275 g/L glucose, 0.1 g/L FeSO4·7H2O, 10.5 g/L MgSO4·7H2O, 2.6 g/L 
sodium citrate·dihydrate, 2.4 mg/L MnCl2·4 H2O, 3 g/L (NaPO3)6, 3 g/L ammonium 
carbonate, 210 g/L yeast extract, 100 µg/ml kanamycin, 36 µg/ml chloramphenicol 
and 4 mM IPTG) was initiated.  A pH-control feed approach was then used to control 
the feeding rate.  Since IPTG was added to the feed, SSX2 production was induced 
while the feed was added.  Samples were taken for analysis of wet cell weight (WCW) 
and SSX2 concentration during the fermentation.  For WCW and glucose 
concentration, a 1.0 ml sample of the broth was collected and centrifuged at 13,000 x 
g for 10 minutes.  The supernatant was collected for glucose concentration analysis 
(Glucose Assay Kit, Sigma-Aldrich, St. Louis, MO) and the cell pellet was weighed to 
determine WCW. 
Purification of recombinant SSX2 antigen 
Cell homogenization, inclusion body wash and solubilization  
1 L of fermentation broth with 260 g of wet cells was lysed with an 
EmulsiFlex-C3 microfludizer (Avestin, Ontario, Canada) for three passes at peak 
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pressure of 20,000 psi.  The cell lysate was then washed with 16 L Tris buffer (50 mM 
Tris base, 100 mM NaCl, 1 mM EDTA and 1 mM 2-mercaptoethanol, pH 7.8) and 8 L 
Phosphate buffer (100 mM sodium phosphate, 0.5 M NaCl, and 1 mM 2-
mercaptoethanol, pH 7.2) using a tangential flow filtration system equipped with a 
0.45 µm pore size centramate cassette (Pall, East Hills, NY) that has minimum 
effective filtration area of 0.09 m2.   The 500 ml retentate, which contained the 
inclusion bodies and cell debris, was collected and solubilized in a 3000 ml buffer (8.7 
M urea, 100 mM sodium phosphate and 1 mM 2-mercaptoethanol, pH 7.5) to a final 
urea concentration of 7.5 M.  
Immobilized metal (nickel) affinity chromatography (IMAC)  
The solubilized protein fractions were filtered with 1.2 and 0.5 µm dead-end 
membrane filters (Pall) in tandem.  The filtrate was then loaded on a 500 ml HiTrap 
Fast Flow IMAC column (GE Healthcare, Piscataway, NJ) which had been 
equilibrated with IMAC buffer A (4 M urea, 100 mM sodium phosphate and 1 mM 2-
mercaptoethanol, pH 7.5).  The chromatographic separation was carried out using an 
AKTA Explorer (GE Healthcare).  After solubilized protein fractions were applied to 
the IMAC column, the column was washed with 5% IMAC buffer B (4 M urea, 100 
mM sodium phosphate, 500 mM imidazole and 1 mM 2-mercaptoethanol, pH 7.5), 
and SSX2 was then eluted with 100% IMAC elution buffer B.  The eluted fraction 
containing SSX2 was buffer exchanged (4 M urea, 50 mM Tris and 1 mM 2-
mercaptoethanol, pH 8.0) and concentrated to 450 ml by a tangential flow filtration 
system with a 10 kDa cut-off centramate cassette (Pall) that has minimum effective 
filtration area of 0.09 m2. 
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Anion-exchange chromatography 
Anion-exchange chromatography was performed by using a 5 ml Q Sepharose 
High Performance (Q HP) column (GE Healthcare) which had been equilibrated with 
AEX buffer A (4 M urea, 50 mM Tris and 1 mM 2-mercaptoethanol, pH 8.0). A total 
of 6 ml of the buffer-exchanged SSX2 fraction from IMAC was applied to the Q HP 
column.  SSX2 was mainly eluted during a step gradient of 40% AEX buffer B (4 M 
urea, 50 mM Tris, 1 M NaCl and 1 mM 2-mercaptoethanol, pH 8.0). Fractions 3 to 5 
(Figure 2-5) were collected and pooled for the next purification step.  
Hydrophobic interaction chromatography 
Anion exchange elution fractions containing SSX2 were mixed with an equal 
volume of pre-HIC addition buffer (4 M urea, 50 mM Tris, 1.4 M ammonium sulfate 
and 1 mM 2-mercaptoethanol, pH 8.0).  A total of 30 ml of this solution was loaded 
onto a 5 ml Phenyl-Sepharose High Performance (Phenyl HP) column (GE 
Healthcare) which was equilibrated with HIC buffer B (4 M urea, 50 mM Tris, 1 M 
ammonium sulfate and 1 mM 2-mercaptoethanol, pH 8.0).  SSX2 was then eluted in a 
step gradient of 50% HIC buffer A (4 M urea, 50 mM Tris and 1 mM 2-
mercaptoethanol, pH 8.0). 
SDS-PAGE and immunoblotting  
Samples were analyzed for SSX2 by electrophoresis on 12% SDS-
polyacrylamide gels (Invitrogen).  After electrophoresis, the gels were stained by 
SimplyBlue SafeStain (Invitrogen).  For western blot analysis, the proteins were 
transferred to a nitrocellulose membrane by electrophoresis and SSX2 was detected 
with 2.5 µg of murine anti-human SSX2 monoclonal antibody (24) using a 
WesternBreeze kit (Invitrogen).  All assays were performed according to 
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manufacturer’s instructions.  
Protein concentration 
Total protein concentration was determined by a Coomassie (Bradford) protein 
assay kit (Pierce Biotechnology, Rockford, IL) using bovine serum albumin protein as 
a standard.  SSX2 concentrations were estimated from scanned images of the 
developed western with Image J densitometry software (http://rsb.info.nih.gov/ij).  
Western blots were scanned and images with SSX2 protein bands were selected, 
plotted and compared with an SSX2 standard.  The purity of SSX2 was determined by 
estimating the total amount of SSX2 as compared to the total amount of protein in 
each sample.  
Endotoxin concentration 
Endotoxin in different chromatographic preparations were quantified by using 
a Limulus Amebocyte Lysate (LAL) Endosafe Endochrome-K kit (Charles River 
Laboratories, Wilmington, MA) according to the manufacturer’s instructions.   
Samples were diluted in LAL Reagent water and 100 µl aliquots were added to a 96 
well plate before the addition of 100 µl of a chromogenic substrate.  The kinetic 
colorimetric data of samples were collected by TECAN GENios microplate reader 
(TECAN Group Inc., Mannedorf, Switzerland).  All assays were performed in 
triplicate and the average value was presented. 
Enzyme-link immunosorbent assays  
10 µl/well of 1 µg/ml purified recombinant SSX2 in a coating buffer (15 mM 
Na2CO3, 30 mM NaHCO3 and 0.02% NaN3, pH 9.6) was added to a well of TC 
microwell plates 60 × 10 (Nunc, Roskilde, Denmark) and incubated overnight at 4°C.  
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Plates were washed with phosphate buffered saline (PBS) and blocked overnight at 
4°C with 10 µl/well of 2% BSA/PBS. Then 10 µl/well of serum diluted in 2 % BSA 
was added and incubated for 2 h at room temperature.  Plates were washed again, and 
10 µl/well of diluted secondary antibody (Goat anti-human IgG-AP, Southern 
Biotechnology, Birmingham, AL) with 2% of BSA was added and incubated for 1 h at 
room temperature.  Plates were washed, incubated with 10 µl/well of Attophos 
substrate solution (JBL Scientific, Obispo, CA) for 25 minutes at room temperature. 
Fluorescence was immediately read by a plate reader (CytoFluor 2350, Millipore, 
Bedford, MA) at the wavelength of 580nm. 
Results  
Effect of pRARE on expression of SSX2 
E. coli C41 (DE3) bearing the pET9a24aNHSSX2 plasmid was induced and 
the soluble and insoluble protein fractions were analyzed.  SSX2 was produced at the 
concentration of 13.9 mg/ml and accumulated mainly as inclusion bodies (Figure 2-1b 
and 2-1c). In order to increase SSX2 expression, we coexpressed pET9a24aNHSSX2 
with a pRARE plasmid, which codes for rarely used tRNA in E. coli.  The production 
of SSX2 antigen in cell cultures with both plasmids was 22.4 mg/ml, a 1.6 fold higher 
production than E. coli cultures bearing pET9a24aNHSSX2 only (Figure 2-1b and 2-
1c).  Because of its potential for producing a higher amount of SSX2 antigen, the 
transformant carrying both pET9a24aNHSSX2 and pRARE plasmids was used to 
scale up in a 2 L fermentor.  
Large scale production of SSX2 in 2 L fermentor  
The production profile of SSX2 is illustrated as Figure 2-2.  At 5.5 hours of 
cultivation, feeding was initiated, and the production of SSX2 was induced.  After  
  49 
 
Figure 2-2. Production profile of SSX2 in E. coli C41 (DE3) harboring 
pET9a24aNHSSX2 and pRARE plasmids cultivated at 37oC using 2 L fermentor. The 
arrow indicates the time of feed initiation. The asterisk indicates the feed of oxygen. 
▲, SSX2 concentration; ■, wet cell weight; ○, glucose concentration; WCW, wet cell 
weight 
 
 
Table 2-1. Total protein, SSX2 concentration and percent recovery in preliminary 
steps of the purification process from cell lysis through IMAC elution 
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induction, glucose concentration was maintained below 0.1 g/L.  At 21 hrs of  
cultivation, inlet air was supplemented with oxygen to maintain a dissolved oxygen 
level of 40% air saturation.  During the fermentation, the amount of cell biomass and 
the quantity of SSX2 increased steadily throughout the induction period at a rate of 6.7 
mg/ml/hr and 39 mg/L/hr, respectively.  After cultivation for 32 hrs and 1.2 L feed had 
been added, the cell biomass reached 260 mg/ml and approximately 1.1 g/L of SSX2 
antigen had been produced. 
Purification of SSX2  
In the large scale fermentation, SSX2 was also mainly accumulated in the 
insoluble fraction (Figure 2-3).  Therefore, after cells were lysed, the inclusion bodies 
were washed and soluble proteins were discarded.  During the wash, roughly 12 g or 
71% of total protein (as measured by Bradford) was removed by TFF with limited 
SSX2 antigen loss in the permeate (Figure 2-3 and Table 2-1).   The retentate was 
solubilized and applied to the IMAC column.  In this purification step, the 
flowthrough and low imidazole steps removed a fair amount of protein impurities with 
531 mg or 60% loss of SSX2.  However, the purity of SSX2 in the high imidazole 
elution was improved from 13% to 34% (Table 2-1 and Figure 2-4).  The 
chromatogram and SDS-PAGE of eluted fractions from anion exchange are shown in 
Figure 2-5.  SSX2 was mostly eluted at 400 mM of NaCl and its purity was further 
improved to 43% (Table 2-2).  The 3.44 mg of eluted SSX2 was then loaded on a third 
chromatography column, a 5 ml Phenyl HP column, which utilized hydrophobic 
interaction.  SSX2 was mainly eluted at an ammonium sulfate concentration of 500 
mM, while the high molecular weight protein impurities eluted at an ammonium 
sulfate concentration below 100 mM (Figure 2-6).  The SSX2 product from the entire 
purification process was over 87% pure and the yield was 20% (Table 2-2). Based on  
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Figure 2-3. Coomassie-stained SDS-PAGE (a) and western blot (b) of SSX2 antigen 
fractions prior to chromatography. Lanes: 1, molecular weight marker; 2, SSX2 
standard; 3, soluble protein fraction of cell lysate; 4, insoluble protein fraction of cell 
lysate; 5, total cell lysate after microfludizer; 6, Tris wash retentate; 7, Tris wash 
permeate; 8, phosphate wash retentate; 9, phosphate wash permeate; 10, 7.5 M urea 
solubilized fraction. Samples of lane 7 and 9 were concentrated before loading on the 
gel  
 
Figure 2-4. FPLC loading and elution profile of solubilized SSX2 antigen applied on 
500 ml immobilized metal (nickel) affinity chromatography (IMAC, Ni-NTA) 
column. F3, flow through fraction; F4, wash fraction; F5, elution fraction. Blue line 
indicates absorbance at 280 nm and gray line represents percentage of IMAC B buffer.  
Inset: Coomassie-stained SDS-PAGE of fractions from IMAC chromatography. M, 
molecular weight marker; S, SSX2 standard 
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Figure 2-5. Anion exchange chromatography profile of 6 ml buffer-exchanged high 
imidazole fraction on 5 ml Q Sepharose HP column at pH 8.  SSX2 antigen was 
mainly eluted at 400 mM of NaCl. Blue line indicates absorbance at 280 nm and gray 
line represents percentage of anion exchange B buffer. Fractions 3 to 5 were collected 
and pooled for HIC process. Inset: Coomassie-stained SDS-PAGE of fractions derived 
from anion exchange chromatography. Lane numbers correspond to chromatogram 
fraction numbers. M, molecular weight marker; S, SSX2 antigen standard 
 
 
Figure 2-6. Hydrophobic interaction chromatography (HIC) profile of SSX2 antigen 
peak fractions from Q Sepharose HP column on a 5 ml Phenyl-Sepharose HP column. 
SSX2 antigen was mainly eluted at 0.5 M ammonium sulfate. Blue line indicates the 
absorbance at 280 nm and gray line represents percentage of HIC buffer B. Inset: 
Coomassie-stained SDS-PAGE of fractions derived from hydrophobic interaction 
chromatography. Fractions 3 to 7 were collected as final purified SSX2 antigen. Lane 
numbers correspond to chromatogram fraction numbers M, molecular weight marker; 
S, SSX2 antigen standard 
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the current scale, it is estimated that a total of 236.3 mg of SSX2 can be produced per 
liter of fermentation. 
Endotoxin assay 
Samples were collected at each stage of the purification process and analyzed 
for endotoxin content (Table 2-2).  The endotoxin content of the buffer-exchanged 
fraction obtained after IMAC was 107 EU/µg of total protein.  Anion exchange 
chromatography further decreased endotoxin nearly five-fold to 23 EU/µg of total 
protein.  After hydrophobic interaction chromatography, SSX2 antigen elution 
fractions had an endotoxin level of 0.11 EU/µg of total protein, a 209-fold reduction. 
Immunological reaction of SSX2 with human sera  
Sera from eight cancer patients, some of whom had anti-SSX2 antibodies, were 
tested for reactivity to purified recombinant SSX2 (Table 2-3).  All three sera that 
have been previously shown to have anti-SSX2 antibodies reacted with the 
recombinant SSX2 and the titer of the sera against the recombinant SSX2 correlated 
with known antibody activities.  Patients’ sera that had been reported to not contain 
anti-SSX2 antibodies did not react with the purified SSX2.  Together, these results 
indicate that SSX2 produced in this study was able to be specifically recognized by 
anti-SSX2 antibodies from the sera of cancer patients.      
Discussion 
It has been shown in several studies that coexpression of a pRARE plasmid can 
improve recombinant protein expression and solubility in the cytoplasm due to the 
increased supply of rare tRNAs for E. coli in situ (5, 11).  In this study, we also found 
that coexpression of SSX2 with pRARE plasmid increased SSX2 production  
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Table 2-2. Total protein, SSX2 antigen concentration, percent recovery and endotoxin 
content of anion exchange and hydrophobic interaction chromatography  
 
 
Table 2-3. ELISA activity of selected human cancer serum with SSX2 antigen purified 
from this study  
    1: The anti-SSX2 antibody activity of the sera from cancer patients (unpublished data). 
    2: SSX2 antigen purified from this study. 
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1.6-fold when the number of cells was normalized.  In order to further increase SSX2 
production, a 2 L fermentation incorporating a fed-batch strategy was used to achieve 
high cell density and SSX2 productivity.  Studies have showed that a fed-batch 
production scheme has advantages for the production of recombinant proteins in E. 
coli (22).  Normally high production rates will lead to acetic acid accumulation due to 
an insufficient oxygen supply or the presence of excess glucose in the medium.  
Accordingly, it is crucial to control the DO level and glucose concentration during a 
fermentation (7) .  It is reported that feeding strategies using DO or pH as an indicator 
can prevent acetic acid accumulation and promote recombinant protein production 
(12).  Therefore, in this study, the DO level was maintained over 40% of air saturation 
by supplying oxygen into the fermentor when agitation and sparging with air only 
would not have been able to satisfy oxygen demand. Additionally, a pH-controlled 
feed approach was used to optimize the glucose supply.  In such a process, cells are 
kept near glucose starvation by using pH to control the glucose feeding rate (13).  
IPTG was added to the feed medium instead of being added to the fermentor in a 
single dose.  This strategy is based on the idea that the concentration of IPTG in the 
fermentation will increase with cell mass ensuring it is at a concentration sufficient for 
induction.  Together these strategies provide steady increase in both cell biomass and 
SSX2 allowing cell biomass and SSX2 produced to reach 260 mg/ml and 1105 mg/L 
respectively at the end of the fermentation.     
Since SSX2 was produced mainly as inclusion bodies necessitating their 
concentration, our purification process targeted the insoluble protein fraction. 
Centrifugation and TFF are the two most common methods used to collect inclusion 
bodies (3, 21).  Our previous work has shown that protein loss is minimized when TFF 
is used instead of centrifugation.  Additionally, scale-up of centrifugation can be 
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difficult (10), hence we focused on TFF.  In this study, our data also showed that TFF 
washes effectively retained approximately 78% of SSX2 (Table 2-1).  
The addition of His-tags aids in the purification of a protein and is not an 
impediment to the use of recombinant proteins in human clinical trials (9, 15).  
Approximately 60% of SSX2 was lost in the flowthrough and wash fractions from the 
IMAC chromatography.  We found that loss of SSX2 in the flowthrough was not a 
result of exceeding the binding capacity of this IMAC column; a western blot of the 
flowthrough fractions showed a similar concentration of SSX2 in all fractions (data 
not show). The composition and conformation of a protein dictates the binding affinity 
in IMAC (28).  The inability of the majority of the SSX2 to bind to the IMAC may be 
the result of aggregation that occludes the His-tag and prevents it from binding to the 
Ni-NTA groups.  
Anion exchange chromatography was used to further purify the SSX2.  
Although the anion exchange did not significantly remove host proteins contaminants 
as compared to IMAC and HIC, it did reduce endotoxin content five-fold.  It has been 
reported that anion exchange chromatography can remove endotoxin from E. coli-
derived recombinant proteins (25).  Endotoxin in recombinant biopharmaceuticals can 
cause a variety of acute inflammatory responses in humans, and endotoxin levels are 
an important criteria for the quality of a biopharmaceutical (17).  Since this process is 
developed with the intention of using SSX2 in human clinical trials, removing 
endotoxin through anion exchange chromatography was deemed to be an integral part 
of the purification process.  
Hydrophobic interaction chromatography (HIC) not only improved the purity 
of SSX2, but it reduced the endotoxin level 209-fold to 0.11 EU/µg of total protein.  
Due to its predicted high hydrophilicity, it is not surprising that SSX2 antigen eluted at 
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a higher ammonium sulfate concentration than the high molecule weight impurities 
which eluted toward the end of the chromatography.  Several studies have 
demonstrated that endotoxin will bind to the HIC matrix (23, 27) and elute at the end 
of the gradient due to its hydrophobic nature (data not show).  This also indicates that 
the HIC process is crucial for acquiring pure SSX2 antigen with low endotoxin levels. 
Finally, in this study, we also performed an ELISA assay to characterize the purified 
SSX2 antigen. CT antigens including SSX2 are known to be expressed 
heterogeneously in cancer patients (6).  The SSX2 antigen prepared in this study 
retained the functionality of being able to be recognized specifically by sera of cancer 
patients who have anti-SSX2 antibodies.  In summary, we reported a production and 
purification process to produce the SSX2 antigen with reasonable yield, high purity 
and low endotoxin content that should be sufficient for further scale up.  
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CHAPTER 3 
PROCESS DEVELOPMENT IN SSX2 CANCER VACCINE PREPARATION FOR 
CGMP PRODUCTION 
Abstract  
SSX2 is a Cancer Testis antigen expressed in a wide variety of cancers including 
synovial sarcoma and melanoma. Humoral and cellular immune responses against 
SSX2 gene products have been described making SSX2 an attractive vaccine target for 
cancer immunotherapy. For the purpose of human Phase I/II proof-of-principle clinical 
trials, SSX2 has been expressed in E. coli C41(DE3) and produced in a 2 L scale of 
fermentation and purification. Further process developments were made to a 
previously reported process to improve its production yield, endotoxin level and 
purity. The yield and purity from anion exchange chromatography were enhanced by 
changing the buffer from Tris to phosphate. A secondary anion exchange 
chromatography was introduced later in the process specifically for endotoxin 
removal. This process decreased the endotoxin level from 4300 EU/mg to 20 EU/mg, 
a 215-fold reduction. A 10 L scale development run for SSX2 production at the 
Cornell/LICR cGMP Bioprocess Facility, which produced 420 mg of SSX2 with 
endotoxin level less than 40 EU/mg and purity over 97%, is also presented. The 
purified urea-solubilized SSX2 was refolded on metal affinity chromatography with a 
yield of 80%. The secondary structure of refolded SSX2 was characterized by Circular 
Dichroism and approximated that it is comprised of 23% alpha helix, 19% of beta 
sheet and 58% of random coil.  
Huang C-J., Newton, S. B., Chen, H. R., Anderson, A. K., Damasceno, M. L., Ritter, 
G., Old, . L., Batt A. C. Process development for SSX2 cancer vaccine preparation for 
cGMP production. Manuscript to be submitted, Cornell University. 
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Introduction 
Cancer is a group of diseases caused by the growth and spreading of abnormal 
cells or cancer cells. It is one of the top life-threatening diseases in the United States: a 
total of over 1.4 million new cancer cases and half million of deaths is projected in 
2008 (9). Although the treatments for cancers, including surgery, radiotherapy, 
chemotherapy and hormone therapy, have been established and combinations of these 
therapies have been applied, cancer still causes 25% of mortalities. Therefore, 
immunotherapeutic approaches to treat cancers or cancer immunotherapy have 
developed in recent years as an alternative modality of cancer treatment. Unlike other 
therapies to eradicate tumor cells by radiation or drugs, cancer immunotherapy, which 
includes passive and active immunotherapy, aims to bolster a patient’s immune system 
to destroy existing cancer cells (14). Passive immunotherapy uses tumor specific 
monoclonal antibodies to target tumor cells to attack tumor cells or block the factors 
that enable a cancer to grow or to spread (18). Active immunotherapy, however, relies 
on the administration of a cancer vaccine, a tumor-specific antigen or peptide, to 
generate anti-cancer immune responses. It aims at raising both cellular and humoral 
immune responses against cancer cells to kill cancer cells (10).  
Cancer-Testis (CT) antigens are one class of these tumor specific antigens that 
are an expanding family of targets for active cancer immunotherapy.  CT antigens are 
highly tumor-specific: the genes encoding CT antigens are expressed in different 
tumors, but they are not expressed by normal tissues with exception of testis germline 
cells. Fortunately, germline cells are MHC class I negative, thus not recognize by 
cytotoxic T lymphocytes, making CT antigens ideal targets for cancer immunotherapy 
(13).  Today, the clinical trails of CT antigens, MAGE A3 and NY-ESO-1, as cancer 
vaccines have shown good results (6, 10), suggesting that active immunotherapy is a 
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promising treatment for cancers. 
Synovial sarcoma X break point 2 (SSX2), belongs to a highly homologous 
family that encodes proteins involved in a chromosomal translocation 
t(X;18)(p11.2;11.2) characteristically found in 70% of human synovial sarcoma (4). It 
is also known as HOM-MEL-40, a CT antigen identified from a melanoma tumor, that 
is also expressed in different malignancies, including colon cancers, hepatocarcinoma, 
and breast carcinoma (17). Both cellular and humoral immune responses against SSX2 
antigen have been described in literatures, making SSX2 an attractive cancer vaccine 
candidate for active cancer immunotherapy (2, 13). In contrast to conventional 
oncology drug development which is designed for cytotoxic agents, cancer vaccines 
require more flexible and developmental guidelines to address their therapeutic 
effects. In 2006, Cancer Vaccine Clinical Trial Working Group (CVCTWG) proposed 
a clinical development paradigm for cancer vaccines and related biologics (7). It 
suggested that a proof-of-principle trial should be introduced in advance to a minimum 
of 20 patients to establish safety database and to demonstrate biological activity of 
cancer vaccine candidates. Therefore, sufficient quantities of potential cancer vaccines 
must be produced under current Good Manufacturing Practice (cGMP) guidelines 
beforehand to perform this proof-of-principle trial. 
To evaluate the efficacy of SSX2 as a cancer vaccine, we previously reported 
the production and purification of SSX2 from Escherichia coli C41(DE3) in a 2 L 
bench-top fermentor (8). In the present study, changes to the previous process have 
been explored to improve protein yield and quality. The result of a development run of 
the new process at Cornell/LICR cGMP biologics is included. Finally, urea-
solubilized SSX2 was refolded, and was characterized by Circular Dichroism. From 
this study, we aim to provide information necessary to produce sufficient amount and 
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high quality of recombinant SSX2 for cancer vaccine trials. 
  
Materials and methods 
Strain construction and preparation of recombinant SSX2   
The construction of the expression strain and preparation of SSX2 protein were 
as previously described (8) with slightly modifications. In brief, the full length of 
SSX2 (Genbank accession No. NM175698) was tagged with six histidine residues on 
its N-terminus and cloned into the plasmid pET9a24a to create expression plasmid 
pET9a24aNHSSX2. E. coli C41(DE3) bearing pET9a24aNHSSX2 and pRARE 
plasmid, which encodes tRNAs rarely used in E.coli, was used as a SSX2 production 
strain. A single colony of it was inoculated in 5 ml LB medium (1% tryptone, 0.5% 
yeast extract and 0.5% NaCl) and grew at 37°C overnight before being transferred to 
40 ml of fermentation medium (0.1 g/L FeSO4·7H2O, 3 g/L (NaPO3)6, 2.1 g/L NH4Cl, 
1.9 g/L citric acid·H2O, 2 ml/L 30 % NH4OH, 15 g/L yeast extract, 20 g/L glucose, 3.2 
mM MgSO4·7H2O, 0.2 mg/L MnCl2·4H2O, 100 µg/ml kanamycin and 36 µg/ml 
chloramphenicol) to allow the optical density (OD600) to reach 2.0. This culture was 
used to inoculate a 2 L fermentor (Bioflo 3000, New Bronswick Scientific, Edison, 
NJ) with an initial volume of 800 ml of fermentation medium connected with a 
fermentation feed (275 g/L glucose, 0.1 g/L FeSO4·7H2O, 10.5 g/L MgSO4·7H2O, 2.6 
g/L sodium citrate·2H2O, 2.4 mg/L MnCl2·4H2O, 3 g/L (NaPO3)6, 3 g/L ammonium 
carbonate, 210 g/L yeast extract, 100 µg/ml kanamycin, 36 µg/ml chloramphenicol 
and 40 mM IPTG). At the end of the batch phase, a fed-batch fermentation was 
initiated by a pH-state control until the end of the fermentation. The cells were 
harvested, centrifuged and lysed, and the SSX2 inclusion bodies were washed then 
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solubilized in 7.5 M urea as previously described (8). The solubilized SSX2 was 
loaded on a 500 ml immobilized metal cheating chromatography (IMAC) column 
(Chelating Sepharose Fast Flow, GE Healthcare, Piscataway, NJ), and the eluted 
SSX2 was subjected to a buffer exchange with Tris buffer A (4 M urea, 50 mM Tris, 
pH=7.5) or AEX buffer A  (4 M urea, 50 mM phosphate, pH=7.5). All 
chromatographic separation was carried out using AKTA explorer (GE healthcare). 
Anion exchange chromatography and endotoxin removal 
A total of 120 mg of buffer exchanged SSX2 in Tris buffer A was loaded on 
150 ml of Q sepharose High Performance resin (QHP, GE Healthcare).  SSX2 was 
eluted at a step gradient of 30% Tris buffer B (4M urea, 50mM Tris, 1 M NaCl, 
pH=7.5). Eluted fractions were collected and pooled for analysis. A similar 
experiment was performed by using the phosphate buffer, and SSX2 was also eluted at 
a step gradient of 30% AEX buffer B (4 M urea, 50 mM phosphate, 1 M NaCl, 
pH=7.5) for 6 column volumes. The SSX2 eluted using the phosphate buffer was 
mixed with an equal volume of HIC loading buffer (4 M urea, 50 mM phosphate, 2M 
ammonium sulfate, pH=7.5) and loaded on a 50 ml Phenyl High Performance (Phenyl 
HP, GE Healthcare) column that had been equilibrated with HIC buffer A (4 M urea, 
50 mM phosphate, 1 M ammonium phosphate, pH=7.5). SSX2 was then eluted at a 
linear gradient at 50% AEX buffer A. The pooled SSX2 fractions were then buffer 
exchange with AEX buffer A and this material was used to study endotoxin removal 
by QHP and Q sepharose XL (QXL, GE Healthcare) columns. A total of 10 mg of this 
buffer exchanged SSX2 was loaded on 5 ml QHP and QXL columns, respectively, and 
followed by eluting at a step gradient of 30% AEX buffer B. The endotxin levels and 
protein concentrations in the flow through and eluted fractions were collected and 
analyzed.   
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Production and purification of SSX2 in cGMP facility  
Fermentation and midstream processing 
A 0.5 ml of glycerol stock of the SSX2 production strain was inoculated in a 
40 ml of fermentation medium and grown overnight at 37℃.  This culture was 
inoculated in a 300 ml of fermentation medium for 2 to 3 hrs until the OD600 reached 
2.0 and, this was used as inoculum of fermentor. The fermentation was carried out in a 
New Brunswick Scientific BioFlo 4500 bioreactor with an initial volume of 7 L 
fermentation medium. The pH, temperature, D.O. controls and feed strategy were as 
previously described (8). A 9.0 L fermentation feed was prepared and added into the 
fermentor during the fed-batch phase until the end of the fermentation. Cells were 
centrifuged, and collected cell pellets were disrupted by a microfludizer 
(Microfluidics, Newton, MA) at a pressure of over 20,000 psi. The SSX2 inclusion 
bodies were washed with Tris (50 mM  Tris, 100 mM NaCl and 1mM EDTA, pH7.8) 
and phosphate buffer (100 mM sodium phosphate and 0.5M NaCl pH 7.2) by 
tangential flow filtration system equipped with a 0.2 µm pore size centramate cassette 
(Pall East Hill, NY). After wash, SSX2 was concentrated to 500 ml and solubilized for 
4 hrs at a final urea concentration of 7.5 M.  
Chromatographic purification of SSX2  
Immobilized metal cheating chromatography (IMAC) 
Solubilized SSX2 was applied to a 4500 mL Chelating Sepharose Fast Flow 
IMAC column, and washed with 5% IMAC buffer B (4 M urea, 50 mM phosphate, 
500 mM imidazole, pH=7.5). SSX2 was then eluted with 100% IMAC buffer B and 
buffer exchanged with AEX buffer A by tangential flow filtration system equipped 
with a 10 kDa cut off pore size centramate cassette (Pall).   
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QHP anion exchange chromatography 
The buffer exchanged SSX2 was loaded on a 3000 mL Q sepharose HP 
column which had been equilibrated with AEX buffer A. Elution of SSX2 was 
performed at a step gradient of 30% AEX Buffer B as indicated previously. The SSX2 
elute was buffer-exchanged again with AEX buffer A by tangential flow filtration 
system equipped with a 10 kDa cut off pore size centramate cassette (Pall). 
Hydrophobic interaction chromatography 
Buffer exchanged SSX2 was mixed with an equal volume of HIC loading 
buffer and load on the 2500 ml Phenyl HP column that have been equilibrated with 
HIC buffer A. SSX2 was then eluted at a linear gradient with of 40 to 50% of HIC 
buffer A. the pooled SSX2 fraction was buffer exchanged again with AEX buffer A as 
previously described.  
QXL anion exchange chromatography 
SSX2 was then loaded on 1000 ml QXL column equilibrated with AXE buffer 
A and chased with two column volumes AEX buffer A. The flow through fraction, 
where the majority of SSX2 was located, was collected for analysis.  
Refolding of SSX2 on IMAC 
A total of 5 mg of purified SSX2 was loaded onto a 5 ml IMAC column. The 
bound protein was refolded using a linear gradient of AEX buffer A and B buffer (50 
mM phosphate, pH=7.5). After an additional three column volumes wash of B buffer, 
the refolded SSX2 was eluted with C buffer (50 mM phosphate, 0.5 M imidazole, 
pH=7.5). To remove the salts, the column elution was buffer exchanged into 10 mM 
phosphate (pH 7.5) buffer and analyzed by circular dichrosim.  
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SDS-PAGE and immunobloting 
Protein samples containing SSX2 were analyzed on 10 or 12% SDS 
polyacrylamide gel electrophoresis (PAGE) under denaturing conditions. Gels were 
stained by SimpleBlue Safe strain (Invitrogen, Carlsbad, CA) for an hour and then 
detained in water for 16 hrs. For western blot analysis, proteins were electroblotted 
onto a nitrocellulose membrane and SSX2 was detected with 2.5 µg of murine anti-
SSX2 antibody using a WesternBreeze kit (Invitrogen) according to manufacturer’s 
instructions.  
Protein concentration 
Total protein concentration was determined by a Coomassie (Bradford) protein 
assay kit (Pierce Biotechnology, Rockford, IL) by using different concentrations of 
bovine serum albumin (BSA) protein as standards. 10 µL of different protein samples 
were added to a 96 well plate, and, 295 µL of Coomassie reagent was added to each 
well. After incubation at room temperature for 10 mins, the absorbances of different 
samples at 595 nm were collected by a TECAN GENios microplate reader (TECAN 
Group Inc., Mannedorf, Switzerland). Protein concentration of each sample was 
determined by the BSA standard curve. SSX2 purity was estimated from a scanned 
image of the final bulk SSX2 protein from a coomassie gel with Image J densitometry 
software (http://rsb.info.nih.gov/ij). The lane was scanned, plotted and compared 
SSX2 with other proteins in the lane to determine its purity. 
Endotoxin assay 
 Endotoxin in different protein samples was quantified by using a Limulus 
Amebocyte Lysate (LAL) Endosafe Endochrome-K kit (Charles River Laboratories, 
Wilmington, MA). Samples were diluted in LAL Reagent water and 100 µL aliquots 
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were added to a 96 well plate before the addition of 100 µL of a chromogenic 
substrate according to manufacturer’s instructions. The kinetic colorimetric data of 
samples were collected by TECAN GENios microplate reader (TECAN Group Inc.,).  
All assays were performed in triplicate and the average value was presented. 
Circular Dichroism (CD) Spectrometry and protein secondary structure 
predictions 
CD spectra of refolded SSX2 was obtained with an Aviv 400 Circular 
Dichorism Spectrometer (Aviv Biomedical, Lakewood, NJ). Protein concentration of 
0.05 mg/ml of SSX2 in 10 mM phosphate buffer was scanned by far-UV (190 to 260 
nm) wavelength at 25°C. The data from three independent runs were corrected for CD 
signals from the buffer and averaged. For deconvolution of CD spectra, the original 
data were analyzed by the k2d software (http://www.embl-
heidelberg.de/%7Eandrade/k2d.html) to predict the secondary structure of refolded 
SSX2.  The predicted secondary structures from primary SSX2 sequence was carried 
out on PredictProtein server (12) 
 
Results and discussion 
Improved yield by using phosphate buffer in anion exchange 
chromatography  
In the previous process, the anion exchange chromatography had shown that 
even though the endotoxin decreased by five-fold, the protein yield was 54% with 
limited improvement in protein purity (8). In order to improve the recovery yield, 
phosphate buffer was used and compared its protein yield with original Tris buffer. As 
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indicated in Table 3-1, the total protein recovery in SSX2 elution fractions was 67% in 
phosphate buffer compared to 51% in Tris buffer. The total protein recovery for 
Phosphate and Tris buffer were 85% and 55%, respectively. FPLC chromatograms and 
gels of different fractions from two anion exchange processes were shown in the 
Figure 3-1. Unlike Tris buffer, host proteins were removed in the flow through by 
Phosphate buffer. These results suggested that, in Tris buffer, some proteins, including 
SSX2 and host proteins, were bound to the resin even after the 1 M NaCl wash, 
leading to low protein recoveries in both peak fractions and total protein content. This 
might be caused by the lower solubility of SSX2 protein solution in 4M urea Tris 
buffer indicated by cloudiness after buffer exchange from IMAC elute (data not 
shown). Since the phosphate buffer improved protein yield in the anion exchange, it 
was used throughout the purification process. 
 
Endotoxin removal by Q Sepharose XL 
It is known that endotoxin can be removed from protein solution by anion 
exchange chromatography due to its negatively charged property. However, this 
method is generally applied to remove endotoxin from basic proteins which are 
repelled by anion-exchanger (11). Since SSX2 is an acidic protein (pI=6.2), the 
clearance factor of endotoxin is limited to around three to five fold by using Q 
Sepharose HP (QHP) resin. To effectively reduce endotoxin, a similar but bigger bead 
size resin, Q Sepharose XL (QXL), was tested. As shown in Figure 3-2 (A and B), 
unlike QHP, 65% of SSX2 was found in the flow through fraction of QXL and its 
endotxin was at the concentration of 20 EU/mg (Figure 3-2 D). It decreased the 
endotoxin level from 4300 EU/mg to 20 EU/mg, a 215-fold reduction. In addition, the 
the SSX2 found in the eluted fraction contained higher molecular weight impurities,  
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Table 3-1. Comparison of protein recovery of Tris and Phosphate buffer in anion 
exchange process   
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Figure 3-1. Comparison of FPLC loading and elution profiles of SSX2 antigen applied 
on 150 ml anion exchange column (Q Sepharose HP) by using Tris (A) and Phosphate 
(B) buffers. Solid line indicates absorbance at 280 nm and dash line represents 
percentage of buffer that contained 1 M NaCl. Inset: Coomassie-stained SDS-PAGE 
of fractions from AXC chromatography. M, molecular weight marker; S, SSX2 
standard; B, raw material before loading; F2 to F9 indicate different fractions collected 
during the chromatography.  
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suggesting that even though protein yield was compromised, the purity of SSX2 was 
improved in the flow through fraction (Figure 3-2 C). In QHP, however, 91% of SSX2 
was eluted in the gradient with an endotoxin concentration of 1250 EU/mg with no 
significant improvement in protein purity (Figure 3-2 C). QXL was able to remove 
endotoxin more efficiently than QHP. The average particle size of QXL resin is 90 µm 
which is about three times larger than QHP (34µm). In addition, agarose beads of 
QXL consist of dextran arms conjugated with quaternary amino group. These two 
characteristics make protein binding and release slower in QXL (16). Our data suggest 
that the slower binding of SSX2 to the QXL resin may actually reduce the binding 
between SSX2 and quaternary amino group, eluting SSX2 in the flow through 
fraction. However, the binding of endotoxin was not affected as indicated by both low 
endotoxin in the flow through and high concentration of endotoxin in the gradient 
eluted fraction. This allowed SSX2 to be separated from endotoxin by using QXL 
resin.  
 
10 L scale development run in cGMP facility 
Because the yield was improved by Phosphate buffer and endotoxin removal 
was enhanced by using a QXL column, a new purification process to produce SSX2 
antigen was developed (Figure 3-3). Phosphate buffer was used for chromatographic 
steps. QXL was added as a final step to polish SSX2 protein including endotoxin 
removal. A development run using this new process was scaled-up in the 
Cornell/LICR Biologics cGMP facility. The result of the fermentation was 
summarized in the Table 3-2 that the OD600 of E. coli was 166.5 and the wet cell 
weight reached 280 g/L at the end of the fermentation. A total of 10 L cell broth was 
harvested for SSX2 purification. The total protein concentration and endotoxin content  
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Figure 3-2. Endotoxin removal of SSX2 antigen by different anion exchange resins. 
After hydrophobic interaction chromatography, SSX2 was loaded on (A) QHP and (B) 
QXL columns to study the effects of endotoxin reduction (D). SSX2 was mainly 
eluted in the salt gradient in the QHP column while most of the SSX2 was 
accumulated in the flow through (FT) in the QXL column. SDS-PAGE (C) also 
showed the difference in protein purity in these two different anion exchange columns. 
M, molecular weight standard; S, SSX2 standard. 
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of each purification step was illustrated in the Table 3-3. The SDS-PAGE and western 
blot of different purification samples were shown in the Figure 3-4. At the end of 
purification, a total of 420 mg of SSX2 was produced, and over 97% pure of SSX2 
was obtained with endotoxin content of 40 EU/mg. The material produced in this 
batch was qualified for safety including low endotoxin content, low nickel content and 
sterility. SSX2 identification was confirmed by MALDI-TOF mass spectroscopy, and 
its molecular weight was determined to be about 22.4 kDa (data not shown). The 
results from this development run demonstrated that the new process is plausible to be 
implemented in our cGMP facility to produce qualified SSX2 for future clinical trails. 
 
 Refolding of SSX2  
The purified and urea-solubilized SSX2 was refolded on an 5 ml IMAC 
column. In this process, 5 mg of SSX2 was loaded onto the column and washed with 
urea buffer. A gradient of 4 M urea and phosphate buffer was applied to the column to 
gradually changing urea concentration from 4 M to zero in phosphate buffer. The 
bounded SSX2 was eluted with phosphate buffer containing 500 mM imidazole. The 
FPLC chromatogram of the refolding process was shown in the Figure 3-5 A.  A total 
of 80% of soluble SSX2 was recovered in the eluted fraction (Table 3-4).  Neither sign 
of cloudiness nor precipitates were found in the eluted fraction (Figure 3-5), indicating 
that the refolded SSX2 was stable in the phosphate buffer. Since soluble SSX2 had not 
been characterized in the literature, it was scanned at Far-UV wavelength by a CD 
spectrometer to analyze its secondary structures (Figure 3-6). The chromatogram was 
deconvoluted to approximate the fractions of each secondary structure type. The 
refolded SSX2 was estimated to contain 23% of alpha helix, 19% of beta sheet and 
58% random coils compared to 19.5% of alpha helix, 9.3% beta sheet and 72.2%  
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Table 3-2. Summary of the cell growth and characterizations of SSX2 production 
strain during the fermentation process. 
 
 
Table 3-3. Summary of total protein concentration and endotoxin content in different 
purification steps from a 10 L fermentation broth containing SSX2 antigen at 
CU/LICR cGMP Biologics Facility.  
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Figure 3-3. A modified SSX2 production process used for a 10L scale development 
run in Cornell/LICR cGMP Biologics. The red rectangle and wording indicate the 
modifications made to the previously reported process.  
 
 
 
 
 
 
 
 
Figure 3-4. SDS-PAGE (A) and Western Blot (B) of SSX2 in different downstream 
purification steps. Lanes: 1, cell lysate; 2, phosphate wash retentate; 3, IMAC load; 4, 
QHP load; 5, QHP elute; 6, HIC load; 7, HIC eluate; 8, QXL load; 9, QXL elute; 10, 
QXL flow through. M, molecular weight marker.  
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random coils that directly delineate from primary sequence of SSX2 (12).   
In order to activate cancer specific cytotoxtic T lymphocytes (CD8+) to attack 
cancer cells, the antigens are delivered to Antigen Presenting Cells such as Dendritic 
Cells (DC). In DC, the intake antigens are sorted into MHC class I and class II 
processing pathways that active CD8+ and CD4+ lymphocytes respectively (19). 
Although CD8+ cells are the main effectors in antitumor immune responses, the 
activation of CD4+ promotes the growth and help memory maintenance of CD8+ cells 
(15). Several studies have suggested that addition of intact soluble antigen to DC 
would majorly in entry of MHC class II processing pathway that activate the CD4+ 
cells (1, 5). Therefore, the purpose to generate soluble SSX2 is to provide clinical 
immunologists another format of SSX2 antigen that can be used in combination with 
urea-solubilized SSX2 to monitor anti-cancer responses both in vitro and in vivo.   
In June 2007, the result of Phase II proof-of-concept clinical trial of CT 
antigen MAGE-A3 in MAGE-A3 positive patients with stage IB or II Non-Small Cell 
Lung Cancer was announced. This trial analysis showed a 33% reduction in the 
relative risk of cancer recurrence following surgery in patients treated with the 
MAGE-A3, compared to placebo (3). A randomized and controlled Phase III safety 
and efficacy clinical trail of MAGE-A3 has been carried out. Several Phase I/II 
clinical trials of another CT antigen NY-ESO-1, to different cancers are also in 
progress (6). These promising results have shown that active immunotherapy by CT 
antigens can provide alternative and effective treatment to cancers. Together with 
more insight and information provided from the clinical trials from these two CT 
antigens, it is foreseeable that more CT antigens, including SSX2, will be tested for 
their efficacy as cancer vaccines. In this study, we have improved yield and quality of 
SSX2, and performed a development run in the Cornell/LICR cGMP Biologics  
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Figure 3-5. Refolding of urea-solubilized SSX2. (A) Refolding of SSX2 antigen by 
immobilized metal affinity chromatography (IMAC). 10 ml of urea-solubilized SSX2 
was loaded on a 5 ml column and protein was refolded by a gradient using 4M urea 
and 100 mM phosphate buffers. Solid line indicates absorbance at 280 nm and the 
dash line represents percentage of phosphate buffer, and then eluted with 500 mM 
imidazole buffer. (B) SDS-PAGE of unfolded SSX2 (1), refolded SSX2 (2) and the 
supernatant of refolded SSX2 after centrifugation (3), indicating that SSX2 was 
soluble in 100mM phosphate buffer, and (4) SSX2 standard. M, molecular weight 
marker. 
 
Table 3-4. SSX2 protein recovery after refolding on the IMAC column 
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Figure 3-6. Circular Dichroism spectra of refolded SSX2 in 10 mM phosphate buffer 
pH 7.5.The spectra was deconvoluted to contain 23 % of alpha  helix, 19% of beta 
sheet and 58% of random coils.  
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facility. These data will provide invaluable information to producing a cGMP grade 
SSX2 for a proof-of-principle clinical trail in the near future.  
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CHAPTER 4 
IMPROVED SECRETION OF THE CANCER TESTIS ANTIGEN SSX2 IN Pichia 
pastoris BY DELETION OF ITS NUCELAR LOCALIZATION SIGNAL 
Abstract 
The Cancer-Testis (CT) antigen SSX2 was expressed in Pichia pastoris as a means to 
produce a delayed-type hypersensitivity skin test reagent for monitoring SSX2-
specific immune response. SSX2 was detected intracellularly in P. pastoris despite the 
addition of the Saccharomyces cerevisiae alpha mating factor secretion signal. 
Increasing SSX2 copy number did not improve its secretion, but did enhance 
intracellular SSX2 levels. SSX2 with the C-terminal nuclear localization signal (NLS) 
deleted, (SSX2NORD), however, was secreted. Indirect immunofluorescence 
indicated that SSX2 with the NLS did not translocate to the nucleus, but accumulated 
in the endoplasmic reticulum (ER). Experimental results further suggested that SSX2 
with the NLS was misfolded in the ER, while deletion of the NLS facilitated correct 
folding of SSX2 inside the ER and improved its secretion.  Production of SSX2NORD 
was scaled-up to a 2 L fermenter using a fed-batch protocol to maintain methanol at 1 
g L-1.  Decreasing the cultivation temperature from 25°C to 16°C improved protein 
stability in the culture supernatant. In this process, after 120 hrs cultivation, the wet 
cell weight of P. pastoris reached 280 mg mL-1 and the yield of SSX2NORD was 21.6 
mg L-1. 
 
Huang C-J., Anderson, A. K., Damasceno, M. L., Ritter, G., Old, J. L., Batt A. C. 
Improved secretion of the cancer testis antigen SSX2 in Pichia pastoris by deletion of 
its nuclear localization signal. Manuscript submitted for publication. 
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Introduction 
The synovial sarcoma X break point 2 or SSX2 gene belongs to a highly 
homologous family (SSX) that encodes proteins involved in a chromosomal 
translocation t(X;18)(p11.2;q11.2) characteristically found in 70% of human synovial 
sarcoma (11). The translocation of synovial sarcoma translocation gene (SYT) on 
chromosome 18 with an SSX gene (mainly SSX1 and SSX2) creates a SYT-SSX 
fusion protein which is believed to be a possible transcription activator for aberrant 
transformation of synovial sarcoma (28). SSX2 is a nuclear protein that contains a 
bipartite nuclear localization signal (NLS) at its C-terminus that is responsible for the 
localization of SSX2 and SYT-SSX2 fusion to the nucleus (16). SSX2, also referred to 
as HOM-MEL-40 or CT5.2a, is an immunogenic tumor antigen identified by the 
serological analysis of recombinant cDNA expression libraries (SEREX) from a 
melanoma tumor (38). It is expressed in various cancers while its expression in normal 
tissue is restricted to the testis. Because of this characteristic expression, SSX2 is also 
known and classified as a Cancer Testis (CT) antigen (18).  
In cancer cells, endogenous cancer antigens are degraded by cytosolic 
proteosome and the resulted peptides can be delivered to the endoplasmic reticulum 
(ER) through transporter associated with antigen processing (TAP). In the ER, these 
cancer-specific peptides are loaded to Major Histocompatibility Complex (MHC) class 
I molecule and presented on the cancer cell surface by the antigen presenting pathway 
(32). Since CT antigens are specifically expressed in cancer and testis cells and testis 
germline cells are MHC class I negative, the expression and activation of CT antigen-
specific cytotoxic T lymphocytes is highly tumor specific, making CT antigens ideal 
targets for cancer immunotherapy. The therapeutic strategy includes delivering CT 
antigens to Antigen Presenting Cells (APC), for example Dendritic Cells, to induce 
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and activate CT antigen-specific T lymphocytes to kill the cancer cells presenting CT 
antigen epitopes (39). Although, SSX2 is a nuclear protein, it has been shown that 
nuclear proteins are partly transported to cytoplasm for degradation (6), therefore the 
presentation of SSX2-specific epitopes are found in cancer cells (4, 8). To date, 
several studies have demonstrated that SSX2 can elicit both humoral and cellular (both 
CD4+ and CD8+) mediated immune responses to kill cancer cells (2, 5, 34). For these 
reasons, there is a considerable interest in producing recombinant SSX2 antigen to 
clinically evaluate it as a cancer vaccine.  
The methylotrophic yeast Pichia pastoris has been widely used for production 
of various recombinant proteins by secretion into the supernatant or by intracellular 
expression (9). The most commonly used transcriptional regulation for recombinant 
protein expression is driven by the alcohol oxidase 1 (AOX1) promoter, which is 
strongly induced in medium containing methanol as a sole carbon source. This 
expression system offers several advantages, such as easy manipulation at the genetic 
level, high stability of transformants, the capability to culture cells at high cell density, 
and most importantly, the ability to perform higher eukaryotic protein secretion and 
post-translational modifications (27). Because P. pastoris secretes low levels of 
endogenous proteins, a secreted heterologous protein constitutes the vast majority of 
the total protein in the culture supernatant (19). The predominance of the heterologous 
protein in the supernatant makes following purification steps easier to implement.  
However, overexpression of heterologous proteins may saturate the secretory 
pathway, with proteins accumulating inside the endoplasmic reticulum (ER) where 
they need to be folded correctly before being transported from the ER to the Golgi 
apparatus (12). Additionally, the options for secretion of heterologous proteins are 
normally limited to foreign proteins which are normally secreted by their native hosts 
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(19). Therefore, one of the challenges in using this expression system is to produce 
and secrete foreign proteins that are not naturally secreted. 
We previously reported the production and purification of SSX2 from 
Escherichia coli C41(DE3) in a 2 L bench-top fermenter with a yield of 236 mg L-1 
purified SSX2 (22).  In this study, SSX2 produced from P. pastoris, rather than E. 
coli, is to be employed for monitoring of SSX2-specific immune responses in a 
delayed-type hypersensitivity (DTH) skin tests and thereby avoiding measurement of 
immunological responses to potential bacterial contaminants in the E. coli-produced 
SSX2 vaccine protein (14). We focus on secretion of SSX2 for purification advantages 
and intend to address the secretion bottlenecks of SSX2 and other nuclear proteins in 
P. pastoris. In this study, we evaluated SSX2 secretion in P. pastoris and found that 
SSX2 is minimally secreted and accumulated inside the cell, mainly in the ER. 
Deletion of its C-terminal NLS improved SSX2 secretion by facilitating its folding 
inside the ER. We also report a fermentation protocol to scale-up the secretion of 
SSX2 without NLS at the yield of 21.6 mg L-1 in the culture media. 
 
Materials and Methods 
Strains and plasmids Construction 
The SSX2 gene (GenBank Accesssion No. NM 175698) was obtained from the New 
York branch of the Ludwig Institute for Cancer Research, cloned into the plasmid 
pcDNA 3.1 (Invitrogen, Carlsbad, CA). All strains, plasmids and constructs created 
and used in this study are shown in Table 4-1 and Figure 4-1. Pichia pastoris KM71H 
and plsmid pPICZαA were purchased from Invitrogen. The SSX2 gene was cloned in 
frame into pPICZαA which uses the Saccharomyces cerevisiae alpha mating factor as 
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a secretion signal and the AOX1 promoter, resulting in pPICZαASSX2. The 
SSX2NORD construct was amplified by oligonucleotides (5’-
GAATTCAACGGAGACGACGCCTTTGCAAGGA-3’ and 5’-
GCGGCCGCTTATCTCTCGTGAATCTTCTCAGAG-3’) using pPICZαASSX2 as a 
template and cloned into plasmid pPICZαA to create plasmid pPICZαASSX2NORD. 
Both plasmids were transformed into P. pastoris KM71H and selected on YPDS 
plates with different zeocin concentrations to create strains MS03, MS-H and MN-H. 
The A33 single chain gene was amplified from plasmid pPIC9K-A33scFv (13) and 
cloned into pPICZαA to create pPICZαAA33scFv. The A33scFvNLS construct was 
amplified by using four oligonucleotides, 5’-
CTCGAGAAAAGAGAGGCTGAAGCTGAGCTCCAGA-3’, 5’-
TTTGGGTCCAGATGAGGAGACGGTGACCAGGGTG-3’, 5’-
ACCGTCTCCTCATCTGGACCCAAAAGGGGGGAACA-3’ and 5’-
GGCGGCCGCTTACTCGTCATCTTCCTCAGGGTCG-3’, using a PCR touchdown 
protocol (15). A33scFvNLS was later cloned into pPICZαA to create 
pPICZαAA33scFvNLS. Plasmids of pPICZαAA33scFv and pPICZαAA33scFvNLS 
were transformed into KM71H to generate strains M33 and M33NLS respectively.  
Strain cultivation and recombinant protein induction  
P. pastoris colonies were transferred to 10 mL YPD medium (1% yeast 
extract, 2% peptone and 2% dextrose) and grown overnight.  The cells were then 
inoculated in 10 mL YPD medium with an initial optical density (OD600) of 0.2 and 
grew for 24 hrs. Cells were harvested and resuspended in 10 mL BMMY medium (100 
mM potassium phosphate, pH 6; 1.34% (w/v) yeast nitrogen base without amino 
acids, 4 ×10-5 % (w/v) biotin, 1% yeast extract, 2% peptone and 0.5% methanol). 
Cultures were then grown in a rotary shaker at 30°C /250 rpm for 16 hrs. In one of the 
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Table 4-1. Strains and plasmids constructed and used in this study 
 
 
 
 
 
 
 
Figure 4-1. Illustration of SSX2 and SSX2NORD constructs. The N-terminal white 
box covers the MHC class one and two epitopes of SSX2 antigen. The C-terminal 
black box represents the nuclear localization signal of SSX2 at its C-terminus. The 
two basic amino acid domains of bipartite NLS are underlined.  
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particular experiment, cells were harvested, washed with PBS (pH 7.5), resuspended 
in BMGY medium (100 mM potassium phosphate, pH 6; 1.34% yeast nitrogen base 
without amino acids, 4 ×10-5% biotin, 1% yeast extract, 2% peptone and 0.5% 
glycerol) and cultivated for 12 hrs. Samples were centrifuged at 13,000 x g for 10 min 
and the culture supernatant and pellet were analyzed.     
Southern blot analysis 
Transformants, including MS03, MS-H, MN-H, M33 and M33NLS, were 
grown in YPD medium overnight in a 5 mL culture. Genomic DNA of these 
transformants was prepared using a Yeaststar genomic DNA kit (Zymo Research, 
Orange, CA) according to manufacturer’s instructions. Different concentrations of 
plasmids (pPICZαASSX2NORD and pPICZα AA33scFv) corresponding to 1 to 10 
copies of SSX2NORD and A33scFv genes were calculated according to the ratio of 
the size of plasmids (4012 and 4322 bp, respectively) to the genome size of P. pastoris 
(9.6 x 106 bp), and used as standards. (20). Both plasmid and genomic DNA were 
digested with restriction enzymes, Xho1 and Not1, at 37°C overnight and run on a 
0.8% agarose gel. The separated fragments were transferred to a positively charged 
nylon membrane (Pall, East Hills, NY) overnight. DIG-labeled probes for both 
SSX2NORD and A33scFv genes were generated using a PCR DIG Probe Synthesis 
Kit (Roche Applied Science, Indianapolis, IN). After DNA transfer, the blot was later 
rinsed, UV-immobilized and hybridized with DIG-labeled probe at 48°C for 6 hrs. 
After washing, the blot was detected with anti-DIG-Fab alkaline phosphatase 
conjugate and developed using a DIG nucleic acid detection kit (Roche Applied 
Science) according to manufacturer’s instructions. DNA fragments on the developed 
membrane were then scanned, selected and plotted by Image J densitometry software 
(http://rsb.info.nih.gov/ij/) and the copy number was determined by the constructed 
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standard curve.   
Indirect immunofluorescence and confocal microscopy 
Induced P. pastoris cells were fixed in 5 mL 100 mM potassium phosphate 
buffer (pH 6.5) containing 5% formaldehyde and incubated at room temperature for 
1.5 hrs. Cells were washed twice with solution B (1.2 M sorbitol, 100 mM potassium 
phosphate, pH 7.4) and converted to spheroplasts by adding 20 µL zymolyase (1 mg 
mL-1) in 500 µL solution B. Washed cells were placed on L-polylysine coated slides 
and permeabilized in -20°C MeOH for 6 min followed by -20°C acetone for 30 sec 
and blocked in PBS/0.1% BSA for 20 min. The cells were then incubated with 5 µg 
mL-1 mouse anti-SSX2 antibody and 10 µg mL-1 rabbit anti-Kar2p antibody.  After 1.5 
hrs incubation at room temperature, cells were washed three times with PBS/0.1% 
BSA and incubated with 20 µg mL-1 of Alexa546-conjugated goat anti-mouse IgG for 
1.5 hrs for indirect immunofluorescence. For confocal microscopy, slides were 
incubated with 20 µg mL-1 of Alexa488-conjugated goat anti-mouse IgG and 20 µg 
mL-1 of Alexa546-conjugated goat anti-rabbit IgG for 1.5 hrs.  Cells were washed 
three times and images were examined. For nucleus staining in immunofluorescence, 
10µg mL-1 of Hochest dye was added into the cells and incubated for 30 min during 
the secondary antibody incubation. Immunofluorescence microscopy was performed 
using an Olympus BX61 epifluorescent microscope (Olympus America, Center 
Valley, PA). Images were acquired using a Cooke SensiCam and Slidebook software 
(Intelligent Imaging, Santa Monica, CA). Confocal microscopy was performed using a 
Leica TCS SP2 system (Leica Microsystems, Bannockburn, IL) and processed using 
Leica Lite software. Images of different emission wavelengths were overlaid to 
examine co-localization. 
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Protein sample preparations from P. patoris 
A 1 mL aliquot of cells from induced strains (Table 4-1) was centrifuged at 
13,000 x g for 10 min. The culture supernatants were collected and proteins were 
precipitated by adding 10 % (v/v) trichloroacetic acid (TCA) and incubated on ice for 
30 min. Supernatant was centrifuged, carefully removed and washed with 200 µL cold 
acetone. Acetone was then removed by centrifugation and protein pellets were dried at 
room temperature for 30 min. A 100 µL aliquot of 1X LDS sample buffer (Invitrogen) 
was added to solubilize the protein pellets and the resulted protein sample was loaded 
on the gel. Cytoplasmic (soluble) and membrane-associated (insoluble) fractions were 
collected as previously described (12). Briefly, the previous cell pellets were washed 
in the phosphate-buffered saline (PBS) at pH 7.4 and resuspended in 100 µL of yeast 
breaking buffer (50 mM sodium phosphate, pH 7.4; 1 mM phenylmethyl sulfonyl 
fluoride; 1 mM EDTA and 5% (v/v) glycerol). 100 µL of acid-washed glass beads 
were added and vortexed at maximum speed seven times for 1 min with 1 min 
intervals on ice to disrupt the cells. The lysate was centrifuged at 14,000 x g for 30 
min at 4°C and the supernatant was collected as the cytoplasmic protein fraction. The 
remaining pellet was resuspended in yeast breaking buffer containing 2% sodium 
dodecyl sulfate (SDS) and centrifuged at 4,000 x g for 5 min. The supernatant was 
collected as the membrane-associated fraction. For whole cell fraction preparation, 
100µL of lysis buffer (50 mM sodium phosphate, pH 7.4; 1 mM phenylmethyl 
sulfonyl fluoride; 1 mM EDTA and 5% (v/v) glycerol; 0.1% Triton X100) and 100 µL 
of acid-washed glass beads were added and vortexed. The cells were then centrifuged 
and the supernatant was collected as the whole cell fraction (30).      
SDS-PAGE and immunoblotting 
TCA precipitated culture supernatants, cytoplasmic, membrane-associated and 
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whole cell fractions were normalized for same cell optical density before analysis. 
Samples were analyzed by electrophoresis on 12% SDS-polyacrylamide gels 
(Invitrogen). After electrophoresis, the gel was stained by SimplyBlue SafeStain 
(Invitrogen). For western blot, the proteins were electroblotted on to a nitrocellulose 
membrane and SSX2 or SSX2NORD was detected with 2.5 µg of murine anti-human 
SSX2 monoclonal antibody using a WesternBreeze kit (Invitrogen). Kar2P (BiP) 
detection was carried out by adding a 1:2,000 dilution of rabbit anti-Kar2p antibody 
(given by Dr. Barlowe). All assays were performed according to manufacturer’s 
instructions. Protein concentrations and protein level comparisons were estimated 
from scanned images of the developed western blots with Image J densitometry 
software (http://rsb.info.nih.gov/ij/). Western blots were scanned and images of the 
protein bands were selected, plotted and compared with standards or a desired band. 
Fermentation  
A 1 mL of overnight culture of strain MN-H was used to inoculate100 mL of 
BMG medium (100 mM potassium phosphate, pH 6, 1.34% (w/v) YNB, 4× 10-5% 
(w/v) biotin and 1% glycerol) and grown at 30°C for 16 hrs until the OD600 reached 
10. This culture was used to inoculate the fermentor (Bioflo 3000, New Brunswick 
Scientific, Edison, NJ). The fermentation was carried out in a 2 L bench-top fermentor 
with an initial volume of 1 L modified BMGY medium with 5% (v/v) glycerol and 
supplemented with 4.35 mL PTM1 trace salts (24 mM CuSO4, 0.53 mM NaI, 
19.87 mM MnSO4, 0.83 mM Na2MoO4, 0.32 mM boric acid, 2.1 mM CoCl2, 0.15 mM 
ZnCl2, 0.23 M FeSO4 and 0.82 mM biotin). AFS-Biocommand Bioprocessing 
software version 2.6  (New Brunswick Scientific) was used for data acquisition and 
parameter control. During the fermentation, dissolved oxygen was maintained at 40% 
air saturation and was controlled by a D.O. cascade of agitation followed by pure 
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oxygen sparging when needed. At the end of the batch phase, indicated by a D.O. 
spike, the culture was induced with a methanol feed (100% methanol with 12 mL 
PTM1 salts/L) and the methanol concentration was controlled at 1 g L-1 throughout the 
fermentation. A methanol sensor, sensor unit and PID control was used to monitor and 
control methanol concentration (13). Samples were taken for analysis of SSX2NORD 
and wet cell weight (WCW) during the fermentation. For WCW, a 1 mL of the broth 
was collected and centrifuged at 13,000 x g for 10 min. The supernatant was collected 
for SSX2NORD analysis, and the cell pellet was weighed to determine WCW.  
 
Results   
SSX2 accumulates intracellularly despite the addition of signal peptide 
In order to express and secrete SSX2 into the culture media, the SSX2 gene was 
cloned into pPICZαA plasmid which carries the S. cerevisiae alpha mating factor as a 
secretion signal. The plasmid, pPICZαASSX2, was transformed into competent P. 
pastoris KM71H cells and the transformants were selected on YPDS plates containing 
100 µg/ml of zeocin. Several transformants including MS03, with one copy of 
pPICZαA SSX2 integrated, were cultivated, induced and fractionated into three 
different cellular fractions. Immunoblot analysis of different fractions revealed that 
SSX2 was poorly expressed, accumulated in the intracellular membrane-associated 
fraction and that the alpha mating factor signal peptide was not processed. No SSX2 
was found in the culture supernatant (Figure 4-2). A high copy number strain MS-H, 
with seven copies of pPICZαA SSX2 integrated, was then selected to test whether 
increasing expression of SSX2 would facilitate its secretion. After induction for 16 
hrs, the expression level of SSX2 found in intracellular membrane-associated fraction 
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increased approximately 49-fold when compared with strain MS03. SSX2 was 
degraded in the soluble cytoplasmic fraction. However, there was only a minute 
amount of degraded SSX2 detected in the culture supernatant fraction (Figure 4-2). 
Thus, we concluded that SSX2 was barely secreted by P. pastoris.        
Deletion of nuclear localization signal (NLS) improves SSX2 secretion 
Because SSX2 is a nuclear protein, it was hypothesized that SSX2 was 
translocated to the nucleus, thus inhibiting its secretion. To confirm this hypothesis, a 
construct of SSX2 without the NLS was created (SSX2NORD) and the plasmid 
pPICZαASSX2NORD was transformed into competent P. pastoris KM71H cells. A 
high copy number strain MN-H, with six copies of pPICZαA SSX2NORD, was 
selected and SSX2NORD expression and secretion levels were compared with the 
native SSX2 expression strain, MS-H. As shown in the Figure 4-3, the SSX2NORD in 
the membrane-associated fraction decreased by 80% as compared to the SSX2 found 
in MS-H strain. There was no sign of SSX2NORD degradation in the soluble 
cytoplasmic fraction. Importantly, SSX2NORD was found in the culture supernatant 
at a concentration of 2.1 mg L-1 as compared with strain MS-H strain that only had a 
minute amount of degraded SSX2 in its culture supernatant. Therefore, there was less 
SSX2 accumulated intracellularly and the secretion of SSX2 was significantly 
improved when the NLS region was deleted. 
SSX2 is not targeted to the nucleus, but accumulates within the ER  
Since there are two competing signal peptides, the N-terminal alpha mating 
factor secretion signal and the C-terminal NLS on SSX2, indirect immunofluorescence 
was performed to localize it and to determine if its translocation to the nucleus was 
inhibiting secretion. Unexpectedly, as shown in Figure 4-4, most of the SSX2 did not  
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Figure 4-2. Secretion of SSX2 at different copy numbers. Western blot of different cell 
fractions of MS03 and MS-H strains that have been induced for SSX2 secretion in 
BMMY medium for 16 hrs. M, molecular weight marker; S, SSX2 standard; 1, 
membrane-associated fraction; 2, cytoplasmic fraction; 3, culture supernatant fraction.  
 
 
 
 
 
 
 
 
Figure 4-3. Effect of deletion of C-terminal NLS on SSX2 secretion. Western blot of 
different cell fractions of MS-H and MN-H strains that have been induced for SSX2 
and SSX2NORD secretion, respectively, in BMMY medium for 16 hrs. M, molecular  
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co-localize with nucleus, indicating that the C-terminal NLS is not functioning to 
direct it to the nucleus. Additionally, as shown in the Figure 4-4B, SSX2 accumulated 
inside the cell, suggesting that SSX2 is possibly retained inside the ER. Confocal 
microscopy was performed to co-localize intracellular SSX2 with the ER-resident 
protein Kar2p. SSX2 did co-localize with Kar2p and mainly accumulated inside the 
ER (Figure 4-5). Thus, SSX2 was targeted to ER by its N-terminal secretion signal. 
For MN-H strain, some SSX2NORD also co-localized with Kar2p, but it was not 
mainly accumulated in the ER and was instead visualized as small dots throughout the 
cell (Figure 4-6). Some of the SSX2NORD might be in the Goligi complex or in the 
secretory vesicles that are in the process of secretion.  
Unfolded protein response is induced and intracellular accumulated SSX2 
is irreversible for secretion  
It is known that accumulation of unfolded and misfolded proteins in the ER 
induces an unfolded protein response (UPR), triggering up-regulation of various ER-
resident proteins, including Kar2p, calnexin and protein disulfide isomerase (PDI) 
(37). Cultures of MS-H, MN-H, KM71 H strain, and KM71H with addition of 10 mM 
Dithiothreitol (DTT) were induced in BMMY medium for 16 hrs and intracellular 
Kar2p levels were compared. DTT is an ER stressor that inhibits correct disulfide 
bond formation, thereby inducing the UPR in cells (33) and was used as a positive 
control. After induction, Kar2p levels in MS-H and MN-H strains were 3.5 and 2.3 
fold higher than the negative control (KM71H) respectively, indicating that the UPR 
was initiated in both strains (Figure 4-7). Nevertheless, UPR was more intensively 
induced in the MS-H strain. The Kar2p level in MS-H strain was similar to the 
positive control which its Kar2p level was 3.9 fold higher than the negative control. T
 The possibility of whether the intracellular accumulated SSX2 and  
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Figure 4-4. Immunofluorescence analysis of the location of SSX2 inside the strain 
MS-H. After cells were induced for 16 hrs. Samples were labeled with Hochest dye 
(A) for nucleus and Alexa flour 546 conjugated with goat anti-mouse antibody (B) for 
SSX2. Images were overlapped in (C). Scale bar, 5 µm   
 
Figure 4-5. Confocal microscopy analysis of the co-localization of SSX2 and ER-
lumenal protein Kar2p or BiP in strain MS-H. SSX2 was stained with Alexa flour 488 
conjugated with goat anti-mouse antibody (A) and Kar2p was stained with Alexa flour 
546 conjugated with goat anti-rabbit antibody (B). Images were overlapped in (C).  
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Figure 4-6. Confocal microscopy analysis of the co-localization of SSX2NORD and 
ER-lumenal protein Kar2p or BiP in strain MN-H. SSX2NORD was stained with 
Alexa flour 488 conjugated with goat anti-mouse antibody (A) and Kar2p was stained 
with Alexa flour 546 conjugated with goat anti-rabbit antibody (B). Images were 
overlapped in (C).  
 
 
 
 
 
 
 
Figure 4-7. Intracellular membrane-associated Kar2p (BiP) levels in MS-H, MN-H 
and KM71H strains after methanol induction for 16 hrs.  Cells were normalized before 
loading on immunoblots. Image analysis was performed using immunoblots from two 
independent experiments. Kar2p level of KM71H strain was normalized as one fold 
and compared its level with other strains and addition of 10 mM DTT that used as a 
positive control for measuring UPR response. 
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SSX2NORD could be processed by cells for secretion was tested. After induction for 
16 hrs, cells of MS-H and MN-H were centrifuged, washed to remove residual 
methanol and resuspended in fresh BMGY medium to stop SSX2 expression. MS-H 
and MN-H were further cultivated in BMGY for additional 12 hrs, and whole cell and 
culture supernatant fractions were analyzed for SSX2 and SSX2NORD in two strains 
at different time points. The intracellular SSX2 in MS-H was degraded over time as its 
intracellular levels decreased and not secreted (Figure 4-8A). In the same experiment, 
however, intracellular SSX2NORD in the MN-H strain was not degraded because the 
increased presence of SSX2NORD was found in the culture supernatant over time 
(Figure 4-8B). Together with previous results, the intracellular SSX2 in the ER could 
not be secreted and therefore degraded. On the contrary, in MN-H strain, intracellular 
SSX2NORD could be processed for secretion.  
Fusion of the SSX2 NLS inhibits the secretion of protein in P. pastoris  
To further characterize the role of NLS in recombinant secretion in P. pastoris, 
a single chain antibody, A33scFv, which is normally secreted was tagged with SSX2 
NLS at its C-terminus (A33scFvNLS). Its secretion was compared with the native 
A33scFv after induction in BMMY medium for 16 hrs. As indicated in Figure 4-9, the 
secretion of A33scFv decreased by 70% when tagged with NLS. This study suggested 
that the NLS of SSX2 may decrease recombinant protein secretion in P. pastoris. 
Scale-up production of SSX2 without NLS  
SSX2NORD production in P. pastoris, was scaled to a 2 L fermentor. 
However, when MN-H strain was cultivated at 25°C, pH 6 and induced for 48 hrs, less 
than 1.3 mg mL-1 of SSX2NORD was found in the culture supernatant and 
SSX2NORD was detected intracellularly (Figure 4-10A).  It was possible that secreted  
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Figure 4-8. The different fates of intracellular SSX2 and SSX2NORD over time after 
their expressions were stopped. Both MS-H (A) and MN-H (B) were induced in 
BMMY medium for 16 hrs. After induction, cells were later centrifuged, washed and 
continued to cultivate in BMGY medium to stop protein expression and cultivated for 
another 12 hrs. Samples were taken at different time points to analyze intracellular and 
culture supernatant SSX2 and SSX2NORD respectively.  M, molecular weight 
marker; SD, SSX2 standard; W, whole cell fraction; S, culture supernatant fraction.  
 
 
 
 
 
 
 
Figure 4-9. Tagging NLS to A33scFv reduced its secretion. After induction for 16 hrs 
in BMMY medium, supernatant of M33 and M33NLS were collected, analyzed and 
compared on the coomassie-stained SDS-PAGE. A33scFv level of M33 strain was 
normalized as one fold and compared its level with A33scFvNLS of M33NLS strain. 
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SSX2NORD was not stable in the culture supernatant and was susceptible to 
degradation under the aforementioned conditions. To improve SSX2NORD stability in 
the culture supernatant, the cultivation temperature was changed from 25°C to 16°C to 
decrease the protease activity in the culture media (24). The corresponding SDS-
PAGE and immunoblot of the samples from these fermentation conditions is shown in 
Figure 4-10B. The stability of SSX2NORD in the culture supernatant was improved 
significantly by lowering the cultivation temperature. The production yields of 
SSX2NORD in the culture supernatant at 72, 102 and 120 hrs were 3.5, 28.6 and 21.6 
mg L-1, respectively. The fermentation profile of SSX2NORD at temperature 16°C, 
pH 6.0 was shown in Figure 4-11. The batch phase was continued for 48 hours until 
the glycerol was consumed, which was indicated by a sharp rise in the dissolved 
oxygen and a decrease in agitation. The methanol feed then started at a steady-state 
concentration of 1 g L-1 until the end of the fermentation. In this process, after 120 hrs 
cultivation, the wet cell weight of strain MN-H reached 280 mg mL-1 and the 
SSX2NORD was produced at a yield of 21.6 mg L-1 in the culture media. 
 
Discussion  
P. pastoris is a robust system to express and secrete recombinant proteins. 
However, many studies including our unpublished data have suggested that some 
proteins are poorly secreted by P. pastoris (31, 40). In this study, when SSX2, a 
nuclear protein and cancer antigen, was expressed and secreted in P. pastoris, the 
protein accumulated intracellularly even with the addition of the alpha mating factor 
secretion signal. Several approaches have been explored in our lab to improve SSX2 
secretion including changes in cultivation conditions (e.g., different cultivation 
temperature, media and pH) and different secretion signals. However, none of these 
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Figure 4-10. Effect of different cultivation temperatures on secretion of SSX2NORD 
in strain MN-H. (A) Western blot of different cell fractions of MN-H cultivated at 
25°C after induction for 48 hrs. (B) Coomassie-stained SDS-PAGE and (C) western 
blot of supernatant of strain MN-H cultivated at 16°C. M, molecular weight marker; S, 
SSX2 standard; 1, membrane associated fraction; 2, cytoplasmic fraction; 3, 
supernatant. In (B) and (C), lane 3 to 6 indicate samples taken at different time points.  
 
 
 
 
 
 
 
 
 
Figure 4-11. Fermentation profile of strain MN-H cultivated at 16°C using a 2 L 
fermentor. During the fermentation, dissolved oxygen (D.O.) was maintained over 
40% of air saturation and pH was maintained around 6. After induction, methanol 
concentration was maintained at 1 g L-1. 
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approaches improved SSX2 secretion (data not shown), indicating that the apparent 
poor secretion is inherent to the protein itself. In addition, increased copy number only 
led to more SSX2 accumulation inside the cells, thus showing that SSX2 is also one of 
the recombinant proteins that are poorly secreted by P. pastoris despite the addition of 
a secretion signal.  
dos Santos and collaborators have demonstrated that SSX2 has a bipartite NLS 
at its C-terminus which is also responsible for its and SYT-SSX2 fusion protein’s 
translocation from the cytoplasm to the nucleus (16).  A study that investigated 
secretion of human tumor suppressor p53 in P. pastoris has hypothesized that NLS at 
the C-terminus of p53 might cause its intracellular accumulation (1). It is reasonable to 
speculate that the C-terminal NLS of SSX2 may inhibit its secretion by translocation 
of SSX2 to the nucleus. SSX2 without NLS (SSX2NORD) was constructed, expressed 
and secreted in P. pastoris and deletion of the NLS significantly improved SSX2 
secretion from no secretion to 2.1 mg L-1 (Figure 4-3). Immunofluorescence however 
showed that intracellular SSX2 did not localize in the nucleus, suggesting that the 
NLS does not function to direct it there. In fact, most of the SSX2 was translocated to 
and accumulated intracellularly mainly in the ER (Figure 4-5). The mechanism of 
improved secretion of SSX2NORD was further investigated. 
Overexpression of heterologous proteins in eukaryotic cells can cause 
saturation of the secretory pathway, mostly accumulating proteins inside the ER (36). 
The accumulation of misfolded proteins inside the ER or an increase in protein traffic 
through the ER will induce UPR to help the cells to cope with the ER stress by up-
regulating levels of ER chaperones (e.g., BiP, calreticulin, calnexin), protein-folding 
enzymes (e.g., PDI, FKB2) (10). Therefore, an increase in Kar2P level is a marker for 
UPR activation in yeast and mammalian cells (26). We found that intracellular Kar2p 
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levels in MS-H was 3.5 fold higher than the KM71H strain and indicates that UPR 
was initiated to help cells cope with secretion stress. In order to know the fate of 
intracellular accumulated SSX2, methanol was removed and fresh BMGY medium 
containing glycerol was added. It is known that the AOX1 promoter is induced by 
methanol and repressed by glycerol (19, 23), thus, recombinant protein expression is 
stopped by changing the media to BMGY. The study suggests that the intracellular 
SSX2 cannot be secreted after protein expression was stopped. Instead, it was 
degraded over time inside the cells presumably by ER associated degradation (ERAD) 
which dislocates misfolded protein across the ER membrane for degradation by 
cytosolic proteasomes (35). Together, these results suggested while expressing SSX2, 
it was misfolded and accumulated in the ER, alarming cell to initiate UPR and ERAD 
responses. 
On the other hand, while compared to SSX2, expression and secretion of 
SSX2NORD in MN-H strain displayed different cellular responses. Deletion of NLS 
improved SSX2 secretion, and decreased intracellullar SSX2NORD. UPR was also 
induced to a lesser extent in SSX2NORD expressing cells, 2.3 fold higher than the 
control strain, which is possibly caused by intracellularly accumulated SSX2NORD 
(Figure 4-3). These results indicated that deletion of NLS improved SSX2 folding in 
the ER, thus facilitated its secretion. Nevertheless, when protein expression was 
stopped, the intracellular SSX2NORD was secreted by the cells over time, indicating 
that by giving cells more time, it will be able to fold and secrete intracellularly 
accumulated SSX2NORD. These experiments also show that even though the 
secretion was improved in SSX2NORD, ER folding or post-ER translocation could 
still be a limiting step for SSX2NORD secretion. This is also supported by the 
confocal microscopy which showed that some of the SSX2NORD accumulated in 
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cells might be in the vesicles. These vesicles might be secretory vesicles waiting for 
secretion. However, it is also possible that some vesicles were targeted to vacuole for 
degradation as seen in other recombinant protein secretion (21), which explains low 
level secretion of SSX2NORD. 
To further characterize the role of NLS in recombinant protein secretion in P. 
pastoris, the NLS of SSX2 was tagged to a well-secreted protein, single chain 
antibody A33scFV, which has been demonstrated to reach a level of 4 g L-1 in 
fermentor cultures (13).  The fusion of the SSX2 NLS reduced the secretion of 
A33scFv by 70% as compared to the native A33scFv. The mRNA expression levels of 
A33scFv and A33scFvNLS in M33 and M33NLS strains did not have appreciable 
difference (data not shown). We conclude that NLS plays a negative role in 
recombinant protein secretion in P. pastoris. It is known that the NLS of nuclear 
proteins are exposed on the protein surface in order to interact and be recognized by 
importin alpha and importin beta for successful nuclear transportation (7, 17). In our 
case, it is possible that exposed NLS on the surface inhibits SSX2 and A33scFvNLS 
folding in the ER, thus preventing or decreasing their secretion, respectively. 
SSX2NORD produced in this study can be used as a DTH skin test reagent as 
well as another format of SSX2 cancer vaccine. Several studies have identified that the 
important epitopes of SSX2 are located at the N-terminus of the protein. The region of 
41-49 amino acid residues of the SSX2 protein is recognized by the tumor reactive 
CD8+ T lymphocytes in association with MHC class I allele HLA-A2. The region of 
19-59 amino acid residues of SSX2 was later identified to be recognized by specific 
CD4+ T lymphocytes in association with MHC class II alleles HLA-DR3, 4 and 11 
and DPI (2, 3, 5, 29). Because the NLS region is downstream of the two important 
epitopes described above, its removal should not impact its utility as another format of 
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SSX2 cancer vaccine.  
Since there are two potential applications of SSX2NORD, the production of 
SSX2NORD was scaled-up in a 2 L bench top fermentor. Surprisingly, there was only 
a minute amount of SSX2NORD found in the culture supernatant when cells were 
cultivated at 25°C, pH 6, while intracellular SSX2NORD was observed at all times. It 
is well-known that high cell density fermentation of P. pastoris is accompanied with 
significant cell lysis, releasing intracellular proteins into the culture medium, including 
vacuolar proteases that cause secreted recombinant protein degradation (24). It is 
possible that secreted SSX2NORD was degraded during the fermentation process. To 
minimize proteolytic instability of secreted SSX2NORD, the MN-H strain was 
cultivated at 16°C to decrease protease activity (25). By changing the cultivation 
temperature from 25°C to 16°C, the stability of SSX2NORD in the supernatant was 
improved significantly; however signs of degradation were still observed as SSX2 
degradation products were shown in the western blot (Figure 4-10C). This indicates 
that decreasing the culture temperature can improve SSX2NORD stability, which 
likely due to decreasing protease activity in the culture supernatant. In this process, it 
was estimated that a yield of 21.6 mg L-1 of SSX2NORD was secreted in the media.  
In this study, we have demonstrated that SSX2 is minimally secreted in P. 
pastoris but mainly aggregates in the ER, and it is not translocated to the nucleus. 
Deletion of NLS from SSX2 improves its folding, thus improving its secretion. Even 
though the secretion of SSX2NORD is improved, folding inside the ER or post-ER 
translocation might still be a limiting step for its secretion. Finally, a protocol to 
produce SSX2NORD in a 2 L fermentor was developed and the secreted SSX2NORD 
can be used as a DTH skin test reagent of SSX2 cancer vaccine. 
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CHAPTER 5 
PROTEOMIC STUDY OF PICHIA PASTORIS CULTURE MEDIA FROM 
DIFFERENT FERMENTATION CULUTRES AND THEIR APPLICATIONS FOR 
RECOMBINANT PROTEIN PRODUCTION  
Abstract  
The proteome of Pichia pastoris secreted into the culture medium during growth in 
fermentor was investigated to identify the protein profile and to enhance the 
purification and secretion of recombinant proteins. Protein samples from culture media 
and two-dimensional (2D) gel spots were subjected to ESI-MS/MS analysis and 
searched against a public fungi genome database. A homology MS-BLAST search 
was also performed to provide information on single peptide hit and unidentified 
proteins. A total of 34 proteins were identified in different fermentation cultures, 
including before and after methanol induction, at different temperatures and in host 
strain overexpressing the recombinant protein Sm-14. In a fed-batch fermentation at 
30°C higher protein concentration and more protein species were observed as 
compared to cultures grown at 25°C. Most proteins identified from culture media from 
P. pastoris have low isoelectric points (pI<6) including naturally secreted proteins and 
some intracellular proteins. EXG1, Gas1p and some cell wall proteins comprised the 
majority of the secreted proteins being idnetified. Intracellular proteins such as alcohol 
oxidase and peroxiredoxin were also found in culture media from P. pastoris induced 
with methanol. This study demonstrates the identity of proteins in the different 
fermentation culture media, and suggests potential biotechnology applications based 
on the discovery of this proteome.  
Huang C-J., Damasceno, M. L., Anderson, A. K., Zhang, S., Baumgart, S., Old, J. L., 
Batt A. C. “Proteomic study of Pichia pastoris culture media from different 
fermentation cultures and their applications for recombinant protein production. 
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Introduction  
 A substantial portion of a cellular proteome is defined as the secretome, which 
ultimately is inclusive of secreted proteins, either anchored on the cell surface or in the 
extracellular milieu, and the proteins involved in secretory pathway (31). Secreted 
proteins, both in eukaryotic and prokaryotic cells, perform a wide range of biological 
functions that are necessary for cells to survive or adjust to environmental changes. 
These proteins have been implicated in cell wall formation, molecular trafficking, 
nutrient scavenging, pathogenicity, and defense against competing species (16). The 
study of secreted proteins can be carried out by directly collecting proteins from the 
extracellular matrix and analyzing them by mass spectrometry. An alternative method 
for identifying secreted proteins is to perform a genome-wide computational analysis 
of the N-terminal peptide of all ORFs for the purpose of predicting secreted proteins 
(29).  However, analysis of the secreted proteome can sometimes be problematic. This 
is mainly due to the limitations in current proteomic technology, including protein 
sample preparation, reproducibility of two-dimensional gel electrophoresis, sensitivity 
of mass spectrometry and completeness of the database utilized (6). Non-secreted 
proteins may also contaminate a secreted protein preparation because of cell lysis 
during the cultivation. In addition, the in silico method to predict secreted proteins has 
an inevitable error rate for both false-positive and false-negative predictions as has 
been reported (16, 30). This is, in part, due to the fact that some secreted proteins are 
not transported by the conventional ER-Golgi pathway (24), hence, those proteins 
cannot be identified based upon consensus N-terminal secretion peptide sequence.  
Nevertheless, scientists are developing new tools and technologies to study the 
secretome because of its importance in understanding fundamental cellular function, 
and developing medical and other biotechnology applications (28).  
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The methylotrophic yeast Pichia pastoris has been used successfully in 
production of various recombinant heterologous proteins from human, animal, plant, 
fungal, bacterial and viral origins (2). The expressed proteins can be produced either 
intracellularly or extracellularly.  However, secretion of recombinant proteins in P. 
pastoris offers several advantages over other systems. Advantages include a folding 
pathway that allows disulfide bond formation and post-translational modifications 
(PTM) which better enables the recombinant proteins to possess their expected 
biological properties.  Secretion of recombinant proteins can also avoid toxicity 
generated from intracellular accumulation of recombinant proteins. In addition, 
extracellular production of recombinant proteins is desirable because it simplifies the 
protein purification process avoiding contamination by all of the intracellular proteins 
(18). These advantages make secretion a popular route for recombinant protein 
production in P. pastoris. However, Pichia also secretes various native proteins into 
the culture medium, and these native proteins must be removed by purification steps. 
To advance the use of P. pastoris, a detailed profile of host secreted proteins regarding 
their identities and physical properties can provide critical insights to improve 
recombinant protein secretion and purification in the P. pastoris system. However, 
there is very little known about Pichia secreted proteins despite its use as a 
recombinant protein production platform for decades. 
To produce large quantities of recombinant protein in P. pastoris, biomass is 
allowed to accumulate during fed batch fermentation. In fermentor culture, where the 
cell growth parameters such as pH, aeration, nutrient and feeding rate can be 
optimized, Pichia reach wet cell weights of over 400 g/L (1). Although several 
recombinant protein expression vectors driven by different promoters have been 
constructed for Pichia, the AOX1 promoter is the most widely utilized and successful 
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system (1,17,18).  A two-stage fermentation process, batch and fed-batch, is typically 
used with strains carrying AOX1 promoter-driven constructs (32). In the batch phase, 
cells are cultivated with an AOX1 promoter repressing carbon source such as glycerol 
to accumulate biomass. Once the glycerol is depleted, the fed-batch addition of 
methanol is started to initiate recombinant protein production. To maintain methanol 
concentration within the tolerance level, three different feeding strategies are normally 
applied. First, the methanol-feeding rate is controlled according to the methanol 
concentration in the culture media, indicated by a methanol sensor (4). Second, 
feeding can be adjusted based on the demand of dissolved oxygen (DO) level in the 
culture media (DO-state) (20). The third strategy is to control the feeding rate 
according to the specific growth rate in the induction phase (3). In addition to the 
methanol feeding strategy, other cultivation parameters including temperature, pH, 
DO and composition of media have also been reported to affect the yield of 
recombinant protein production (17). However, the adjustments of the 
abovementioned parameters to maximize protein production can be protein-specific, 
and require investigation to identify the crucial parameters for protein production in 
fermentor cultures.  
In this study, we analyzed the P. pastoris culture media proteins under 
different fermentation conditions. The protein profiles of different samples cultivated 
from the host strain (X-33) and one expressing a recombinant protein (Sm-14) grown 
at different temperatures, both before induction and after methanol induction, were 
analyzed. We have identified proteins in these culture media on the basis of isoelectric 
point (pI) and molecular weight.  Information attained from this study will enhance 
technology related to recombinant protein purification and secretion in P. pastoris to 
expand its biological applications. 
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Materials and Methods 
Strain and plasmids  
The wild type strain Pichia pastoris X-33 (Invitrogen, Carlsbad, CA) was used 
in all fermentation experiments. The gene sequence of Sm14 (Genbank Accession no. 
AY055467.1) with a C62V mutation was acquired from Integrated DNA 
Technologies, where its genetic codons have been optimized for P. pastoris. The 
Sm14-C64V was cloned into plasmid pPICzαA (Invitrogen) to create plasmid 
pPICzαASm14-C64V transformed into competent X-33 strain to create strain Sm-14.   
Fed-batch fermentation 
A 1.0 mL aliquot of overnight culture of strain X-33 and Sm-14 were used to 
inoculate 100 mL of BMG medium (100 mM potassium phosphate, pH 6.0, 1.34% 
(w/v) YNB, 4 × 10-5% (w/v) biotin and 1% glycerol) and grown at 30°C for 16 hrs 
until the optical density (OD600) reached 20. This culture was used to inoculate the 
fermentor. The fermentation was carried out in a 2.0 L bench-top fermentor (Bioflo 
3000, New Brunswick Scientific, Edison, NJ) with an initial volume of 1.0 L modified 
basal salts medium (0.23 g L−1, CaSO4 · 2H2O, 4.55 g L−1, K2SO4, 3.73 g L−1, MgSO4 
· 7H2O, 1.03 g L−1, KOH, and 6.68 mL L−1, H3PO4, 5% (v/v) glycerol and 0.5 mL 
Antifoam 204 [Sigma, St. Louis, MO]) supplemented with 4.35 mL PTM1 trace salts 
(24 mM CuSO4, 0.53 mM NaI, 19.87 mM MnSO4, 0.83 mM Na2MoO4, 0.32 mM 
boric acid, 2.1 mM CoCl2, 0.15 mM ZnCl2, 0.23 M FeSO4 and 0.82 mM biotin). 
Ammonium hydroxide (15%) was used as a pH control agent and nitrogen source 
during the fermentation. AFS-Biocommand Bioprocessing software version 2.6  (New 
Brunswick Scientific, Edison, NJ) was used for data acquisition and parameter control. 
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During the fermentation, dissolved oxygen (DO) was maintained at 40% air saturation, 
and was controlled by a DO cascade of agitation followed by pure oxygen sparging 
when needed. At the end of the batch phase, indicated by a DO spike, the culture was 
induced with a methanol feed (100% methanol with 12 mL PTM salts/L). The 
methanol concentration was controlled at 1 g L-1 and induced for 24 hrs. A methanol 
sensor, sensor unit and PID control was used to monitor and control methanol 
concentration.  
TCA precipitation 
Fermentation samples were collected and centrifuged at 13,000 x g to collect 
culture supernatant which was filtered through 0.1 µm pore size dead end filter (Pall, 
East Hill, NY).  A total of 2.0 ml of supernatant was pooled and trichloroacetic acid 
(TCA) was added to a final concentration of 10%, and incubated on ice for an hour. In 
the case of the ‘before induction’ fermentation sample, 6.0 ml of supernatant was 
used. Samples were centrifuged, supernatant was removed, and washed three times 
with cold acetone. The residual acetone was removed and protein pellets were dried at 
room temperature for 20 min for further analysis.  For 2D gel samples, protein pellets 
were solubilized in rehydration buffer. For 1 D and in solution samples, 8 M urea was 
added to resolubilize the protein pellets.  
Electrophoresis  
Gel electrophoresis with one dimension (1 D) 
Different protein pellets were solubilized in 8 M urea and normalized to the 
same protein concentration before loading on a gel. Protein samples were analyzed by 
electrophoresis on 12% SDS-polyacrylamide gel (Invitrogen), run at 200 Volt for 1 h. 
After electrophoresis, the gel was stained by SimplyBlue SafeStain (Invitrogen). 
  126 
Gel electrophoresis with two dimensions (2D) 
The 2D gel electrophoresis was performed by the ZOOM IPGRunner System 
(Invitrogen). In the first dimension of isoelectric focusing electrophoresis (IEF), 
protein samples were solubilized in rehydration buffer (2 M thiourea, 5 M urea, 0.8% 
carrier ampholytes (pH 4-7), 2% CHAPS, and 20 mM DTT) and added into the strip 
cassette to rehydrate the 7 cm immobilized pH gradient strips (IPG strip pH 4-7, 
Invitrogen) for 16 hrs.  The IEF was carried out with the following parameters: 200 V 
for 20 min, 450 V for 15 min, 750 V for 15 min and 2000 V for 120 min. After IEF, 
the strips were equilibrated (1X LDS and 50 mM DTT) for 15 min, alkylated (1X LDS 
and 125 mM iodoacetamide) for another 15 min, then placed on top of a 4% to 12% 
gradient SDS polyacrylamide gel (Invitrogen) and sealed with 0.5% agarose. The gels 
were run at 75 V for 10 min and then 200 V for another 40 min, and stained by 
SimplyBlue SafeStain (Invitrogen). A total of 28 spots from three 2D gels were 
excised by scalpel blade and transferred to 0.6 ml tubes for protein identification 
analysis.  
Protein concentration and wet cell weight 
An aliquot of 1.0 ml of fermentation broth was sampled and centrifuged at 
13,000 x g for 10 min. The supernatant was collected for protein concentration 
analysis. Total protein concentration was determined by a Coomassie (Bradford) 
protein assay kit (Pierce Biotechnology, Rockford, IL) by using different 
concentrations of bovine serum albumin (BSA) as standards. 10 to 30 µL of each 
protein sample was added to a 96 well plate and each well received 295 µL of 
Coomassie reagent. After incubation at room temperature for 10 min, the absorbance 
at 595 nm was collected by a TECAN GENios microplate reader (TECAN group Inc., 
Mannedorf, Switzerland). The protein concentration of each sample was determined 
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according to a BSA standard curve. To determine wet cell weight (WCW), after 
supernatant was removed, the cell pellet was weighed to determine WCW.  
Sample preparation for mass spectrometry analysis 
A total of 28 gel plugs were subjected to in-gel digestion by trypsin and the 
resultant digested peptides were extracted for mass analysis as described by 
Shevchenko et al. (27) with slight modifications. After digestion, the supernatant was 
collected and a total of two extractions on a gel plug were performed. First was 30 µL 
of 50% acetonitrile (ACN) with 5% formic acid (FA) for 45 min followed by 30 µL of 
90% ACN with 5% FA for 5 min. All supernatants were combined and dried in a 
SpeedVac concentrator (Thermo Savant, Holbrook, NY). For in solution samples, 5 
µg protein of each sample were collected and subjected to reduction and akylation in 
10 mM DTT and 55 mM iodoacetamide respectively. Protein samples were digested 
with trypsin overnight, added with 20 µL FA and desalted by C18 solid phase 
extraction (SPE) columns. All samples were then dried in a SpeedVac concentrator for 
further analysis.  
Reversed phase HPLC and tandem mass spectrometry (LC-MS/MS) 
The peptide samples were reconstituted with 10 µL of 2% ACN with 0.5% FA. 
A total of 6.4 µL were injected onto a PepMap C-18 trap column (5 µm, 300 µm id × 
5 mm, Dionex) and separated on a PepMap C-18 RP Nano column (3 µm, 75 µm id × 
150 cm, Dionex), using a 30-60 min gradient of 5% to 45% ACN in 0.1% FA at 275 
nL/min to elute the peptides. The NanoLC was connected in-line to a hybrid triple 
quadrupole linear ion trap mass spectrometer, 4000 Q Trap (Applied Biosystems, 
Foster City, CA) equipped with a nano ion source. The ESI-MS/MS data acquisition 
was performed using the analyst 1.4.2 software in the positive ion mode for 
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information-dependent acquisition (IDA) analysis. The nanospray voltage was set at 
2.0 kV for all experiments with nitrogen gas used as both the curtain gas and collision 
gas that the heated interface was set at 150 °C . The declustering potential was set 50 
eV to minimize in-source fragmentation. The ion source nebulizer (gas 1) was set to 
20 (arbitrary unit). For IDA analysis, after each survey scan from m/z 400 to 1600, an 
enhanced resolution scan was carried out with multiple charge states. Rolling collision 
energy based on different charged states and m/z values was used to obtain optimal 
MS/MS spectra.  
Data analysis and protein identification 
The nanoLC-ESI based IDA files used for database searching by MASCOT 
2.2 to search against the NCBI fungi database downloaded in January 2009. The 
search parameters allowed for one miscleavage, and variable modifications of 
methionine oxidation and cysteine carboxyamidomethylation with a peptide tolerance 
of 1.5 Da, and MS/MS tolerance of 0.6 Da for LC-SEI. All matches were above a 95% 
confidence interval (CI) with significant scores defined by MASCOT probability 
analysis (www.matrixscience.com/help/scoring_help.htm#PBM) greater than 
“identity” considered confidentially-hit peptides and used for protein identifications. 
The IDA raw data files were also subjected to MS spectra-based blast homology 
search. The MS BLAST Homology search was carried out by ProBlast search 
software 1.4 (Applied Biosystems, Foster City, CA) for all spots to determine the 
protein homologs in the S. cerevisiae protein database downloaded in April 2009 (25). 
For those peptide hit and unidentified spots, the raw mass spectra were first searched 
against the NCBI Schistosoma database download in April 2009 to eliminate Sm14-
related spots. For the remainder of the protein spots, the top hit of the homolog search 
is shown.  
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Results  
 Preliminary analysis of culture media proteins in different fermentation 
cultures 
The optimum growth temperature for P. pastoris has been reported at 28 to 30 
°C. However, some studies have shown that decreasing temperature below 25 °C can 
significantly improve recombinant protein productivity without hampering cell growth 
(4, 7). To understand the cell growth kinetics and profile of proteins in culture media 
the P. pastoris host strain and derivatives expressing SM-14, several fermentations 
were performed at different cultivation temperatures and their fermentation profiles 
were compared. The cell growth, extracellular protein concentration, and methanol 
utilization of X-33 at 30°C and 25°C, and Sm14 at 25°C are shown in Figure 5-1.  
When X-33 grew at 30°C, the batch phase was 22 hrs and WCW reached 410 mg mL-1 
after methanol induction for 24 hrs. The amount of consumed methanol was 695 g and 
the protein concentration in the media was 0.34 mg mL-1 where both values were 
higher than X-33 cultivated at 25°C (477 g and 0.105 mg ml-1, respectively).  These 
data indicated that cells utilized more methanol at 30°C at induction phase. For the 
Sm14 strain, the WCW and methanol consumption rate were 0.38 mg mL-1 and 341 g, 
respectively, which were lower than that observed for X-33 cultivated at 25°C, 
suggesting that expression of Sm14 C64V affects cell growth and methanol 
consumption. However, the average media protein concentration was 0.145 mg mL-1, 
0.03 mL-1 mg higher than that observed for the X-33 strain grown at 25°C. The SDS-
PAGE analysis of protein samples, for both ‘before induction’ and ‘after induction for 
24 hrs’ of three fermentations is shown in Figure 5-2. Protein species in the samples 
from the ‘before induction’ fermentations did not show obvious differences. However,  
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Figure 5-1. Growth curves, culture media protein concentrations and consumed 
methanol of strain X-33 and Sm14 cultivated in different conditions. Black line, X-33 
at 30°C; Red line, X-33 at 25°C; Blue line, Sm14 at 25°C.  Circle, methanol volume; 
square, Wet Cell Weight (WCW); Triangle,  culture media protein concentration.  
 
 
 
 
 
 
 
Figure 5-2. SDS-PAGE analysis of different fermentation protein samples from X-33 
and Sm14 strains before (lane 1,3, and 5) or after induction for 24 hrs (lane 2,4 and 6). 
M, molecular weight marker. Each lane was loaded with 4 µg of protein. 
  131 
 
Table 5-1. Proteins identified in P. pastoris X-33 before induction with methanol at 
25oC 
 
 
Table 5-2. Proteins identified from the culture medium of X-33 cultivated at 25°C 
after methanol induction for 24 hrs.   
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Table 5-3. Proteins identified from the culture medium of Sm14 cultivated at 25°C 
after methanol induction for 24 hrs. 
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Table 5-4. Proteins identified from the culture medium of X-33 cultivated at 30°C 
after methanol induction for 24 hrs. 
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for the ‘after induction’ samples, the protein species were quite different among three 
different conditions, particularly a diversified protein profile was found in cells 
cultivated at 30°C. To identify proteins present in culture media, four protein samples, 
three ‘after induction’ samples and one ‘before induction’ sample (X-33 at 25°C), 
were collected, TCA precipitated, solubilized in 8 M urea and digested with trypsin. 
The resulted peptides were later separated and analyzed by nano-LC ESI-MS/MS. By 
searching against the NCBI fungi protein database, seven protein species were 
identified in the ‘before induction’ condition (Table 5-1). When both X-33 and Sm14 
strains were cultivated at 25°C, there were six and 13 protein species detected, 
respectively (Table 5-2 and 5-3). From the culture media of X-33 cultivated at 30°C 
(Table 5-4), 18 protein species were identified, which correlated with the observation 
from SDS-PAGE that it had a greater number of protein species. However, both high 
protein concentration and complex protein species in the culture medium at 30°C 
cultivation indicated that this is not a favorable fermentation condition for production 
of recombinant protein from the objective of protein purification. Therefore, samples 
of X-33 and Sm14 cultivated at 25°C were collected to further identify and 
characterize proteins in the respective culture media by using 2D gel electrophoresis.   
2D gel analysis of culture media proteins  
Samples of X-33 and Sm14 cultivated at 25°C were TCA precipitated, 
solubilized in rehydration buffer and loaded on IPG strips to perform 2D gel 
electrophoresis. Preliminary investigations using pH 3-10 strips showed that pIs of 
most culture media proteins were less than 7.0. To have a better resolution of protein 
spots, pH 4-7 strips were used in this study. As shown in Figure 5-3, the vast majority 
of culture media proteins exhibited pI less than 6.0 with molecular weight ranging 
from 10 to 260 kDa. A total of 28 protein spots were excised from three gels, digested 
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with trypsin, analyzed by Nano/LC ESI-MS/MS and a Mascot search against the 
NCBI fungi database was performed to determine the protein identity of each spot. 
Out of 17 spots, there was identity with proteins that have both a high protein score, 
and at least two peptide hits indicating high confidence of the identified proteins 
(Table 5-5). A total of six spots had only single peptide hit proteins and five spots 
failed to yield any identity. As shown in Figure 5-3 and Table 5-5, naturally secreted 
proteins, such as exo-beta-1,3-glucanase, Gas1p and acid phosphatase, were found in 
the culture supernatant, especially exo-beta-1,3-glucanase was presented in 12 excised 
spots. However, intracellular proteins such as alcohol oxidase and peroxiredoxin were 
also identified in the culture media of post-methanol induction samples. These 
proteins are related to methanol metabolism, including methanol utilization and 
protective responses to oxidants generated by methanol oxidation. Protein disulfide 
isomerase and enolase, which are proteins present in both the intracellular and 
extracellular milieu, were also identified. Since most spots were cut from the Sm14 
culture media gel, some spots might be Sm14 or its degradation products. Therefore, a 
MASCOT search against the NCBI Schistosoma protein database was performed for 
all protein spots in order to identify Sm14-related spots.  Spots numbered 18, 21, 25 
were identified as Sm 14 with multiple peptide hits and a high protein score. In total, 
there were eight protein spots, four with one single peptide hit and four unidentified, 
requiring further characterization. It should be note that manual inspection of all raw 
data files which yielded either single peptide hit or no hit found numerous high quality 
MS/MS spectra from multiply-charged precursor ions, suggesting the failure of 
identification for those 2D spot samples is likely due to either no equivalent genomic 
database available or unexpectedly heavy modifications. 
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Figure 5-3. 2D gel images of different samples prepared from culture media of X-33 
and Sm14 strains. In total twenty-eight spots were selected for Nano/LC-MS/MS 
analysis. * Sm14 
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Table 5-5. Protein identification of seventeen 2D gel spots of more than two peptide 
hits.  
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Homology search of single peptide hit and unidentified protein spots  
To provide further information about single peptide hit and unidentified spots 
(low-identity spots) from previous 2D gels, the MS spectra of all protein spots were 
submitted for MS BLAST searches against the S. cerevisiae protein database. For low-
identity spots, seven out of eight protein spots had homologs in S. cerevisiae, and the 
top hit protein of each protein spot is shown in Table 5-6. Spot 16 was identified as a 
superoxide dismutase by MASCOT and as PMR1 protein, a Ca+2/Mn+2 binding 
ATPase, by homolog search. Both are metal chelating proteins with different cellular 
functions. Spots numbered 24, 26 and 28 all had a single peptide hit of a hypothetical 
protein of Candida glabrata. The homolog search identified these spots as Scw4p and 
Scw10p which belong to a class of soluble cell wall proteins with similarity to 
glucanases. For unidentified spots, spot five had a top hit with Sun4p protein which is 
also a cell wall protein with possible function in cell wall septation. Spots of nine and 
20 were identified as Sim1p and Ino80p, respectively, and both proteins were 
indicated as intracellular proteins by their cellular functions.  
 
Discussion 
One of the major limitations in proteomic research is the availability and 
completeness of the protein database. To quickly and correctly identify a protein of 
interest, a comprehensive database is required (9, 15). Nevertheless, a proteomic study 
of an unsequenced organism such as CHO cells could still be carried out by searching 
respective MS spectra against databases of rodent, human or all species (19). Although 
the genome of P. pastoris was sequenced, the database is not free accessibility to the 
public (5). Therefore, in this study, a MASCOT search of all MS spectra generated  
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Table 5-6. MS BLAST search of low confidence 2D gel spots to identify protein 
homologs in Saccharomyces cerevisiae.  
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from the solution samples and the 2D gel spots were performed against the public 
NCBI fungi database which also contains a portion of the P. pastoris protein 
sequences. A detailed analysis of 2D gel spots further provided a better resolution of 
culture media proteins and showed their characteristics such as abundance, pI and 
molecular weight. To complement database weakness, a homolog search of MS 
spectra from all samples against the S. cerevisiae protein database was performed to 
provide additional information for low-confidence protein spots. Without access to an 
available completed P. pastoris protein database, our study provides a novel discovery 
of the proteome in P. pastoris culture media, under different fermentation conditions.  
In the preliminary study, protein concentrations and profiles of before 
induction samples were similar among the different fermentation conditions (Figures 
5-1 and 5-2). After transition to the methanol-consumption phase, protein 
concentration and protein species increased in Sm14-expression and 30°C cultures. 
Particularly cultivation at 30°C has been shown to increase cell lysis and proteolytic 
activity (11). From the MS data of solution samples, alcohol oxidase and other 
intracellular proteins were detected in culture media of the 30°C and Sm14-expressing 
cultures, indicating cell lysis after methanol induction. Several native secreted 
proteins, such as beta-1,3-glucanase, Gas1p, acid phosphatase and Fet3, were 
identified in different culture media, particularly, beta-1,3-glucanase was found in all 
samples. Surprisingly, protein disulfide isomerase (PDI) was detected in the culture 
media of the before induction sample and found to be the dominant protein.  PDI is 
occasionally found in yeast culture media and is mainly located at the endoplasmic 
reticulum (23, 29). Even though we have identified a total of 34 proteins in the 
different fermentation culture media, the number of identified proteins is less when 
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compared to a similar study conducted by Swain et al., which have identified 81 
protein species in the secretome of Kluveromyces lactis (29). This could be attributed 
to a different sample preparation protocol, incomplete P. pastoris database, or in 
reality, P. pastoris secretes lower levels of native proteins (18).  
It is known that the optimal temperature for recombinant protein production in 
P. pastoris is protein-specific and related to other physiological conditions such as pH 
of the media (12). When X-33 was cultivated at 30°C with pH 6.0 in a fed-batch 
fermentation, the extracellular protein concentration reached 0.34 mg mL-1, three 
times higher than that observed in the 25°C cultures. A similar experiment conducted 
by Hong et al., also found that cultivation at 30°C exhibited much higher protein 
concentration in the culture media than cultures at 25°C (10). Regardless of 
temperature effect on recombinant protein production, high concentration of host 
proteins in the culture media represents a great challenge for recombinant protein 
purification. These host proteins are considered as impurity contaminants and must be 
removed during the purification process (33). In addition, SDS-PAGE and MS 
analysis have shown that there were more diversified protein species in the culture 
media of the 30°C cultivation (Figure 5-2 and Table 5-4). Expression of Sm14 at 30°C 
also revealed high host protein concentration in the culture media (data not shown). 
These results suggested that P. pastoris fermentation carried out at 30°C is not a 
favored condition, especially for the objective of recombinant protein purification. 
Therefore, a more comprehensive 2D gel proteome analysis was carried out for the 
25°C cultures. 
From the 2D gel analysis of culture media samples, it was very interesting that 
most proteins have acidic pI. A study of the secretome of Pleurotus sapidus revealed 
that the majority of secreted proteins are metallopeptidases and serine proteases that 
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also have low pI (36). In P. pastoris, however, the identified proteins were more 
diversified including secreted and intracellular proteins. Some protein spots were 
identified as the same protein with identical molecular weight but with different pI. 
This could be a common problem in 2D gel electrophoresis or posttranslational 
modification of the protein (5). Among the secreted proteins, exo-beta-1,3-glucanase 
was identified in 12 of the 28 spots.  These 12 spots showed high protein scores and 
exhibited multiple peptide hits indicating the presence of exo-beta-1,3-glucanase. 
Among the 12 spots, spot 12 had the highest protein score and displayed a reasonable 
molecular weight (47.8 kDa) and pI (4.53) characteristic of exo-beta-1,3-glucanase.  
Other spots may also be exo-beta-1,3-glucanase that shifted their molecular weights 
and pIs due to post-translational modification (glycosylation) and degradation. 
Although research has shown that exo-beta-1,3-glucanase of P. pastoris is not a 
glycoprotein, most of the yeast exoglucanases have proven to be glycosylated (8, 34). 
Hence, a glycostain was done, revealing that most of the higher molecular weight 
spots contained glycoproteins, including spots two, four, 17, 19 and 20 which were 
identified as exo-beta-1,3-glucanase (data not shown). Therefore, it is possible that the 
12 spots of exo-beta-1,3-glucanase are the non-glycosylated form, glycosylated form 
or the degradation fragments of both. Intracellular proteins, including alcohol oxidase, 
peroxiredoxin, and nucleotide diphosphate kinase, were detected in the culture media 
of after induction samples. The presence of these intracellular proteins was due to cell 
lysis, especially alcohol oxidase can account for over 30% of intracellular proteins in 
cultures using methanol as the carbon source (13). The secretome was defined as the 
proteome of the secreted proteins, and the cellular machinery involved in their 
secretion (14). Therefore, this study provides a novel discovery and survey of the 
proteome with a greater range than just the secretome: a real-time analysis of the 
proteins in the fermentation culture media.  
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Homology-driven proteomics is used to explore the proteome of organisms 
with unsequenced genomes to provide reliable sequence similarity identification of 
unknown proteins (26). The so-called MS BLAST approach is based on a unique 
search algorithm which uses direct raw IDA data files as input spectra to perform 
homolog search against the designated database instead of traditional “complete 
match” database search approach.  This MS BLAST strategy has been used to identify 
proteins of P. pastoris by homolog search against the S. cerevisiae genome database: 
15 out of 19 protein bands were successfully identified (25). In this study, that 
approach was used to find S. cerevisiae homologs of single peptide hit and 
unidentified protein spots. Two cell wall proteins (CWPs), Scw4p and Scw10p, linked 
to the cell wall via an alkaline-sensitive linkage were identified. These two proteins 
are related to glucanases with possible functions in mediating cell-cell interactions and 
cell wall biogenesis (35). It is not a surprise to find them present in the culture media. 
Sun4p and Sim1p were also indentified and both belong to the SUN family of S. 
cerevisiae. In the SUN family, genes share 75% to 85% identity of 258 amino acids at 
their C-terminus, but appear to be involved in different cellular functions (22). Sim1p 
is reported to participate in DNA replication and Sun4p is described as a cell wall 
protein involved in cell septation (21).  Using this strategy, seven out eight spots were 
successfully identified to provide supplemental information to the proteome of the 
fermentation culture media.  
Understanding the proteome of the fermentation culture media is important to 
recombinant protein purification and secretion in P. pastoris. First, fermentation is the 
protocol widely used for recombinant protein production. This proteome shows a real-
time host protein profile presented in the culture media. Second, protein 
characteristics, including molecular weight, pI, hydrophobicity, of media proteins can 
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be revealed which can aid recombinant protein purification. For example, if the 
secreted recombinant protein has a basic pI value, anion exchange chromatography 
would be a good choice for the first capture step. Third, several secreted proteins were 
identified and the use of these secreted proteins as fusion protein partners or their 
secretion signals can build a tool box to improve recombinant protein secretion. 
Collectively, this proteome data expands the biotechnology applications of P. pastoris.   
In this study, we have examined the proteome of the culture media of P. 
pastoris under different fermentation conditions. A total of 34 proteins were directly 
identified from solutions of the different culture media. Spots analysis from 2D gels 
allowed identification of more proteins, and revealed some of their characteristics of 
this proteome. These data will enhance methods of recombinant protein secretion and 
purification in P. pastoris. However, the analysis of the proteome is far from complete 
due to the lack of the sequenced P. pastoris genome. Once the genome sequence 
become public, we are hoping to identify more proteins from our techniques to reveal 
more details about this proteome.   
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CHAPTER 6 
CONCLUSIONS AND PERSPECTIVES 
 In this study, two popular recombinant protein expression systems, 
Escherichia coli and Pichia pastoris, have been used to produce cancer vaccine SSX2 
and its DTH skin test reagent. In fact, initial work to secrete SSX2 in P. pastoris to 
take advantage of its folding and secretion pathway to simplify its purification process 
and to avoid contamination of intracellular proteins (9). Various studies have been 
performed to improve its secretion, such as cultivation at different conditions, 
overexpression ER chaperones and foldases, and utilization of different secretion 
signals. These conditions did not significantly improve SSX2 secretion. In addition, 
one of the goals of this study is to produce SSX2 for its proof-of-principle clinical trail 
which requires high protein yield in order to generate sufficient amount of vaccine for 
cancer patients (7). Therefore, E. coli was chosen as expression host for its high yield 
expression of SSX2 and its production and purification process were also developed 
(8).  
SSX2 was purified from E. coli inclusion bodies and solubilized in urea. Like 
other cancer vaccines such as NY-ESO-1 and MAGE-A3, it will be formulated in 4M 
urea and the unfolded SSX2 will be used as a cancer vaccine (3, 10). This is due to the 
fact that Major Histocompatibility Complex (MHC) class one epitopes are generated 
from the degraded peptides, therefore there is unnecessary to maintain the biological 
activity of cancer antigen (11). The therapeutic strategy is to deliver SSX2 to Antigen 
Presenting Cells (APC), for example Dendritic Cells, to induce and activate SSX2-
specific cytotoxic T lymphocytes to target and kill the cancer cells through a process 
called cancer immunotherapy (12, 13). Several studies have demonstrated that SSX2 
can elicit both humoral and cellular (both CD4+ and CD8+) mediated immune 
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responses to kill cancer cells displaying SSX2 epitopes on cell surface (1, 2). 
Therefore, there is an urgent need to scale up the process to produce SSX2 for the 
proof-of-principle trials.  
 For the first part of this work, due to its successful expression in E. coli C41 
(DE3) strain, the production of SSX2 was scaled-up in a 2L fermentor equipped with a 
fed-batch protocol using a pH-state control to reach the high cell density of 260 mg/ml 
and protein yield of 1105 mg/L. The purification method, including cell lysis, 
tangential flow filtration and three chromatographies, effectively removes E. coli 
contaminants from SSX2 antigen. Among all the purification steps, hydrophobic 
interaction chromatography was most effective regarding both contaminant and 
endotoxin removal.   This is due to the fact that SSX2 is a predicted hydrophilic 
protein and endotoxin is characteristically hydrophobic due to it lipid A tail (16).  
Even though this study provides a reasonable yield for SSX2 production, the 
expression of SSX2 seems to be toxic according to the dissolved oxygen (DO) profile 
during the fermentation, a sharp increase in DO after protein induction. Experiments 
to optimize SSX2 expression and cell growth, such as induction time, IPTG 
concentration and different cultivation temperatures, can be carried to avoid the 
toxicity effect of SSX2 expression and maximize its production. In addition, although 
the study also shows that the purified SSX2 can be recognized by the SSX2-antibodies 
from the sera of the cancer patients, the preliminary in vitro or in vivo experiments to 
show the activation of SSX2-specific cytotoxic T lymphocytes by the purified SSX2 
can be performed to demonstrate its anti-cancer immune responses.   
Process development was later studied to improve the protein yield, purity and 
endotoxin level of the SSX2 antigen, and the new process was scaled up to a 20L 
fermentor in the Cornell/Ludwig Institute for Cancer Research cGMP Facility. 
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Phosphate buffer was found to improve SSX2 solubility, therefore increasing the 
protein recovery during the anion exchange process. A fourth chromatography, Q 
sepharose XL (Q XL), was introduced to specifically remove endotoxin and to 
improve the protein purity.  The new process, incorporating phosphate buffer and an 
additional Q XL column, was scaled-up and produced 420 mg of SSX2 with 
endotoxin level less than 0.04 EU/µg and purity of over 97%. The urea-solubilized 
SSX2 was refolded for a potential use as another format of SSX2 cancer vaccine that 
can activate T helper cells (CD4+) to promote the growth and memory maintenance of 
SSX2-cytotoxic T lymphocytes (5). Even though, the scaled-up process produced high 
quality of SSX2, low protein yield was found in the IMAC step due to the geometry 
limitation of the column. Therefore, a proper scaled-up study based on same column 
height or contact time should be conducted in the future to improve the protein yield. 
Additionally, a new process also has been proposed to further improve the protein 
yield (Figure 6-1) where anion exchange Q sepharose HP is eliminated and sodium 
chloride is added both in the load and buffer solution in the Q XL polishing step (5). 
SSX2 was also expressed in P. pastoris as a means to produce a delayed-type 
hypersensitivity (DTH) skin test reagent for monitoring SSX2-specific immune 
response from E. coli-produced SSX2 vaccine. P. pastoris has been reported to 
successfully secrete some recombinant proteins. However, secretion of some other 
recombinant proteins has proven to be difficult resulting in intracellular accumulation 
and low secretion yields (9, 14).  Investigations in SSX2 secretion in P. pastoris 
indicated that SSX2 is also one of the recombinant proteins that are poorly secreted by 
P. pastoris. In the third part of this work, studies showed that SSX2 was misfolded 
and accumulated inside the endoplasmic reticulum (ER). Unfolded protein response 
(UPR) was induced and degradation of intracellular SSX2 was found possibly by the  
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Figure 6-1. A suggested new SSX2 purification process for improving SSX2 
production yield.  The blue X and wording indicate the modifications made to the 
previous reported process.  
 
Figure 6-2. A simplified diagram showing the differences in secretion of SSX2 and 
SSX2 without nuclear localization signal (SSX2NORD) in P. pastoris. 
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activation of ER-associated degradation (ERAD) pathway to help the cells to cope 
with the ER stress (4). Deletion of C-terminal nuclear localization signal (NLS), 
however, significantly improves SSX2 secretion by improving its folding inside the 
ER (Figure 6-2). In addition, tagging NLS to a well-secreted protein, A33 single chain 
antibody, also decreased its secretion by 70%. Therefore, this study suggests that the 
NLS may inhibit or decrease recombinant protein secretion in P. pastoris. A 
fermentation protocol to produce SSX2 without NLS was later developed with yield of 
21.6 mg/L that can be used as the DTH skin test reagent for SSX2 cancer vaccine. 
Even though, SSX2 secretion was improved by deletion of its NLS, its purification 
can be problematic due to its degradation in the culture media. To improve its 
stability, expression of SSX2 without NLS by P. pastoris SMD1168H, a vacuole 
peptidase A (pep4) defective strain (9), should be investigated in the future. Addition 
of protease inhibitors may also be considered as an alternative strategy to improve 
SSX2 stability in the culture media. 
The last part of this work is the study of the proteome of culture media of P. 
pastoris at different fermentation conditions that attempts to improve recombinant 
protein purification and secretion in P. pastoris. Protein samples from culture media 
and two-dimensional (2D) gel spots at different fermentation conditions were 
subjected to ESI-MS/MS analysis and searched against a public fungi genome 
database downloaded in January 2009. A total of 34 proteins were identified directly 
from culture media and 28 gels spots were collected for further analysis. Most 
identified proteins have low isoelectric points (pI<6) including naturally secreted 
proteins and some intracellular proteins. EXG1, Gas1p and some cell wall proteins 
comprised the majority of the secreted proteins being identified. Intracellular proteins 
such as alcohol oxidase and peroxiredoxin were also found in culture media from P. 
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pastoris induced with methanol.  
The proteome data collected from this study can expand the biotechnology 
applications of P. pastoris. First, understanding host cell protein profile can reveal the 
identities of crucial contaminants with regard to the recombinant protein, providing 
strategies to remove these contaminants from the final product (15). Second, the use of 
the identified secreted proteins such as EXG1, Gas1P, Fet3, as fusion protein partners 
or their secretion signals can build a tool box to improve recombinant protein 
secretion. Third, deletion of the non-essential secreted genes can possibly enhance 
secretion of recombinant protein due to a lesser-saturated secretory pathway and also 
increase its predominance in the culture media. In June 2009, the whole genome 
sequence of P. pastoris has published (6). Future study should include searching all 
MS spectra against the new Pichia genome database to identify more proteins 
presented in the culture media. Studies of recombinant protein secretion using 
different secretion signals, such as EXG1, Gas1P and Fet3, should be conducted to 
provide new secretion signals and tools for recombinant protein secretion in P. 
pastoris. 
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